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Antigen presenting cells (APC) express a wide range of surface pattern recognition 
receptors (PRR) that involve in pathogen recognition, phagocytosis, antigen presentation, 
and induction of adaptive immunity. It is known that vaccine adjuvants may act as 
conserved microbial ligands, and function via initiation and manipulation of innate 
immune responses through certain PRRs. Meanwhile, signaling pathways mediated via 
various PRRs may contribute differently to the pathogenicity of exposure to microbial 
ligands and bioactive particulates.
Class A scavenger receptor (SR-A) and Toll -  like receptor 4 (TLR-4) are two types of 
PRRs expressed on the cell surface of APCs. The present study utilized human and 
murine macrophage cell lines to investigate signaling mechanism and potential ligands, 
including lipopolysaccharide (LPS), silica, and airborne particulate matter PM1648, for 
the two PRRs. Biological potency of synthetic lipid A compounds was evaluated with an 
in vitro human cell assay system, and the length of compound secondary fatty acyl chains 
was found to play a critical role in compound immunological potency. With biological 
inhibition assays using monoclonal antibodies, we demonstrated that lipid A compounds 
were signaling through TLR-4. With direct binding assay and binding inhibition studies, 
we indicated a two -  step binding mechanism of LPS to TLR-4 receptor. A possible cross 
-  reactivity between TLR-4 and Fc receptor CD64 was also investigated.
It is clear that PRRs may function individually or cooperatively to direct adaptive 
immune responses following innate ligand recognition. Therefore, the possible 
cooperative mechanism between TLR-4 and SR-A for up-regulating murine APC activity 
in response to LPS, silica, and PM1648 was investigated. Using blocking antibodies and 
receptor deficient murine macrophages, we demonstrated that silica uses both TLR-4 and 
SR-A for signaling in order to activate macrophages efficiently, while LPS and PM1648 
use TLR-4 for macrophage activation. APCs stimulated with silica sent signals other than 
soluble cytokines to T cells for activating host immune responses. SR-A appeared to be 
involved in negative regulation of cell activation by LPS and PM1648, as well as in 
mediating endotoxin and particulate direct binding and clearance.
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CHAPTER 1
Overview of Immune Response, Vaccination, and Immune Cell Surface Receptors
Innate Immunity and Adaptive Immunity
Immunologists have been trying for decades to solve the mystery of how host 
organisms detect and dispose the infectious agents without harming self tissues. Up to 
date, several distinct immune-recognition systems in vertebrate animals have been 
identified to help partially unfold the mystery. These systems fall into two broad 
categories: the “innate immunity” and “adaptive immunity”.
The innate immune system serves as the first line of host defense that detects the 
presence and the nature of an infection, initiates and defines the cell activating signals, 
hence directs the adaptive immune responses. The adaptive immune system, on the other 
hand, functions through the generation of random and diverse antigen -  specific 
receptors, including both T cell -  and B cell -  receptors (TCR and BCR), via the 
mechanism of “clonal selection and expansion”. Furthermore, this mechanism also leads 
to the generation of immunological memory, which is essential for the long -  term 
immune protection and for a successful vaccination.
The specialized phagocytes of immune system, including both macrophages and 
dendritic cells (DC), are responsible for detection and clearance of infectious agents and 
infected host cells, as well as for initiation and connection between innate and adaptive 
immune responses. They are involved in initial capture and processing of potential 
antigens (innate immunity), as well as in antigen presentation and activation of antigen- 
specific T and B lymphocytes (adaptive immunity). In addition to the efficient endocytic
1
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and phagocytic activities, these phagocytes also function as antigen-presenting cells 
(APC) that are able to induce and regulate local and systemic immune responses by 
acting as potent secretory cells which release inflammatory cytokines and chemokines.
Overview of Importance and Application of Vaccination and Adjuvant
Attacks using biological or chemical agents to poison or infect humans and 
animals have been reported since the 14th century. Today, it still remains as a serious 
threat to the world. One recent event (fall of 2001) involved letters filled with B. 
anthracis spores that were mailed to government leaders in the U.S indicating that 
individuals or groups are still actively engaged in obtaining and developing biological 
agents for terrorism use in this country. Therefore, development of vaccines, antisera, and 
therapeutic agents against a wide range of organisms, toxins, and viruses has received a 
great deal of attention in the research field due to the heightened concerns about 
bioterrorism and the use of biowarfare agents.
In the meantime, effective vaccination provides significant benefits to human 
health. Vaccines have been well recognized as one of the most effective and widely used 
pharmaceuticals. The contribution of vaccination to smallpox eradication is a good 
example. Today in the United States, vaccines that can provide effective protection 
against eleven diseases, including polio, measles, whooping cough, diphtheria, and 
hepatitis types A and B, etc, are recommended for use. Data of statistical analysis 
indicated that the annual morbidity resulting from the above diseases has decreased by 
more than 95% for each indication, with the widespread use of these vaccines (31).
2
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Moreover, such great results may still be significantly improved by the combinational use 
of effective adjuvants.
Adjuvants are being developed and utilized to enhance vaccine - induced 
protective immunity by increasing the immunogenicity of certain vaccines, enhancing 
responses in low responder populations, such as the elderly and the immunosuppressed, 
and modulating inappropriate immune responses. The combinational use of vaccine and 
adjuvant can also reduce the amount of antigen required for protective levels of 
immunity, therefore provides an economic benefit as well. Research data indicated that 
adjuvant activity could be mediated through a number of mechanisms, such as providing 
a general inflammatory stimulus, activating antigen presenting cells (macrophages and 
dendritic cells) and lymphocytes, increasing phagocytosis activity, controlling the speed 
of antigen release, optimizing cytotoxic T cell responses by facilitating MHC-I 
presentation, and enhancing long -  term immunological memory, etc.
Up to date, only two types of adjuvants are officially approved and licensed for 
clinical use in human: aluminium salts and MF-59 as part of an inactive flu vaccine (107). 
Some other products are in the late stage of clinical testing, such as monophosphoryl lipid 
A (MPL) and the saponin derivative QS-21. Many more potential products are in clinical 
development or pre-clinical testing stage, including Mycobacterium vaccae, 
cytokine/growth factors, CpG motifs, syntex adjuvant formulation/2 (SAF/2), muramyl 
tripeptide (MTP) and liposomes(105j.
It has been well understood that the immune cells and cytokines of the innate 
immune system play an essential role in the long-term, protective immunity induced by 
vaccination. Various immune cells of innate immune system express pattern recognition
3
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receptors (PRR) on cell surface, such as Toll-like receptors (TLRs) and scavenger 
receptors (SRs), that usually function by direct binding to specific and highly conserved 
microbial components. With cell surface PRRs, the host innate immune system can detect 
microbial infections or vaccines containing highly conserved microbial ligands, and 
activate antigen-presenting cells (APCs), resulting in phagocytosis, antigen presentation, 
and the secretion of inflammatory cytokine and chemokines. Therefore, naive T- and B- 
lymphocytes of the adaptive immune system may be stimulated, and antigen - specific T 
cell receptors (TCR) and B cell receptors (BCR) may be generated by clonal selection 
and expansion. Meanwhile, cytokines and chemokines may continue directing the 
immune response against the microbes by guiding the antigen - specific lymphocyte 
maturation, leading to a long-term, antigen-specific adaptive immunity, which is essential 
for a successful vaccination. This mechanism indicates that certain adjuvant candidates 
may be able to enhance vaccine -  induced protective immunity by mimicking or acting as 
conserved microbial ligands, and triggering innate immune responses through certain cell 
surface receptors (PRRs).
Lipopolysaccharide (LPS), Silica, and Airborne Particulate Matter (PM)
Available research results indicated that lipopolysaccharide and its active lipid A 
component, as well as certain bioactive particulates, including silica and PM, can 
effectively activate the innate immune system and lead to inflammation. Therefore, they 
all possess a potential adjuvant effect.
4
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I. Lipopolysaccharide (LPS)
LPS is the endotoxin that is localized on the surface of bacterial cells, and 
together with phospholipids and proteins, forms the outer membrane of Gram- 
negative bacteria. LPS can produce adverse physiological reactions, including 
circulatory and metabolic failures, and often lethal shock in animals. These effects 
have been attributed largely to the release of several chemical mediators such as 
interleukins, tumor necrosis factor (TNF), and eicosanoids from activated 
macrophages. It is also well known that LPS is able to activate the complement 
cascade and prime polymorphonuclear leukocytes or monocytic macrophages to 
release these various mediators. The in vitro culture of polymorphonuclear leukocytes 
or peritoneal macrophages with LPS promotes an enhanced respiratory burst and 
release of eicosanoids: events considered important in the defense against bacterial 
infections as well as in the progress of tissue damage.
LPS is composed of three distinct structural parts: 1) O-antigenic repeating 
polysaccharide, 2) core-oligosaccharide, and 3) a lipophilic component designated 
lipid A (Figure 1-1). There are considerable variations in the amounts of 
polysaccharide in LPS so that some LPS consists predominantly of lipid A and is so 
called “R-form” LPS, whereas others have abundant polysaccharide (the O-side 
chain) therefore is called “S-form” LPS. Among the three structural parts of LPS, 
lipid A has been well known as a potent stimulator of host immune system, therefore 
it has the potential to act as an adjuvant for vaccine antigens. Meanwhile, due to its 
immunostimulating capability, lipid A may also provide general protections against 
infections by functioning as a strong inducer of non-specific resistance (NSR).
5
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However, even though the lipid A component of LPS is so well known to be 
responsible for the endotoxic activities, the polysaccharide moiety influences the 
elimination kinetics, mediates specific LPS binding to macrophages and lymphocytes, 
and is essential for activation of the alternate pathways of the complement system.
Figure 1 - 1 .  Lipopolysaccharide (LPS) from Salmonella Minnesota R595. Adapted from 
Reference (31).
11. Silica
“Silica” is the general name given to a variety of substances that are 
primarily made up of two elements: silicon and oxygen. The chemical formula 
used for silica is SiCh. Under natural conditions, these oxygen and silicon atoms 
bond together to form a large macromolecular structure, and the fundamental unit 
of this structure is the silicon centered tetrahedron SiO/". These fundamental
6
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units are connected through the oxygen atoms that are shared between the two 
neighboring tetrahedral. Therefore, silica does not exist as a discrete molecule.
There are two natural forms of Silica: the crystalline form and the 
amorphous form (Figure 1 - 2). When found in the crystalline forms, the 
tetrahedra fundamental units are arranged in an orderly sequences which results in 
a repeatable pattern. However, in the amorphous forms, these units are randomly 
oriented so that no structural periodicity can be observed (35>.
Tetrahedron Si O
OOxygen 
.  Silicon
✓V Amorphous silica
Figure 1 - 2. Crystalline and amorphous forms of silica. Adapted from Reference(35).
The pathogenic effect of exposure to crystalline silica on lung disease has 
been known since the 18th century. Among the many diseases associated with 
silica inhalation, chronic and acute silicosis are probably the best known. 
However, after decades of research work, scientists have learned that there are 
many other different physical disorders associated with silica exposure. Some
7
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typical examples include progressive systemic sclerosis, systemic lupus 
erythematosus (SLE), rheumatoid arthritis, dermatomyositis, glomerulonephritis 
(GN) and vasculitis.
Available studies indicated that common mechanisms mediated the many 
different pathogenic responses to silica exposure. Among the involved 
mechanisms, the interaction of silica particles with the immune system has been 
known to play an important role in silica pathogenicity, especially the activation 
of alveolar macrophages by silica stimulation (Figure 1 - 3). Once inhaled and 
contacted with cell membrane, silica particles can be engulfed by macrophages. 
After that, two different pathways may follow: the “successful” pathway or the 
“unsuccessful” pathway. When the engulfed particle is successfully cleared and 
disposed from the lung without causing cell death, the clearance process follows 
the “successful” path. On the other hand, if  the particles activate the macrophages 
and eventually cause cell death, the whole process will then follow the 
"unsuccessful" path. In this case the particles will be released from the dead cells 
and deposited in the lunge. In the meantime, cytokines, chemokines and oxidants 
(ROS, RNS) will be released into the medium as well, sending signals to target 
cells and initiating an ingestion-reingestion cycle, resulting in the recruitment of 
more macrophages and polymorphonuclear (PMN) cells to the site. The 
establishment of such a prolonged cell recruitment will cause inflammation, 
which becomes a critical step for silica -  associated diseases (Figure 1-3).
In addition, proteins or phospholipids adsorbed onto the particle surface 
may be denatured and rendered antigenic properties due to the structural changes.
8
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Thus, free particle inhalation may produce novel antigens, resulting in possible 
autoimmune responses (Figure. 1 - 3). Furthermore, silica has also been found to 
possess adjuvant effects. Silica inhalation may induce immune dysfunctions in 
several ways, such as depressing phagocytic capacities of the reticuloendothelial
Figure 1 - 3. Mechanisms of silica pathogenicity: the activation of alveolar macrophages 
accounts for the many pathogenic responses induced by silica exposure. Adapted from 
Reference <3S>.
III. Airborne Particulate Matter (PM)
The general term “particulate matter” (PM) refers to a mixture of different 
types of particles in ambient air, with different sizes and chemical composition, 
and originating from many different sources. The concept of “PM” has been 
commonly applied in health-related research fields. In urban air, significant 
variations of particle size can been frequently observed, including the tiniest 
particles sized in nanometers, others equivalent to molecular clusters, and some
system and increasing polyclonal antibody synthesis, especially IgA and IgG ° 8’
21,35)
clearance
successful
^  release o f
PMN recruitment * cytokines
i » growth factors * oxidants (NO, H:0 :i
unsuccessful]
fceli death |
pmn + «
autoim m une response
modified adsorbed 
protein e.g 
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very large particles, such as pollen grains and windblown sand. Therefore, the 
general concept of “PM” covers a variety of particle-size categories. The different 
sizes, together with other characteristics of the particles, have been considered to 
have biological significance, and have been well related to particle toxicity. For 
example, particle size and shape may determine the amount of inhaled particles 
that will be deposited in the lung, and these parameters may also define the 
regions of the respiratory system where the inhaled particles will affect.
Evaluating health effects of PM in ambient air is difficult and complicated 
due to the highly diverse size, shape, and concentrations of the particles.
However, scientific studies have developed new techniques and knowledge 
regarding PM health effects in susceptible subpopulations during the past years.
In addition to previously observed adverse health effects, recent studies have 
identified new pathogenic responses associated with PM exposure, particularly on 
cardiovascular health effects and for children and older adults with asthma. 
Several common themes have been recognized and reported lately(20,23,25), 
including the connection between PM exposure and exacerbation of existing 
asthma conditions among children and older adults, and the adverse health effects 
of PM exposure on population in general, and more specifically, on those with 
cardiovascular and respiratory illnesses.
It has been well known that inflammation may lead to a series of systemic 
effects, such as acute-phase responses with increase blood viscosity and 
coagulability. Therefore, the initiation and continuous presence of an 
inflammation response has been an important issue for mechanistic studies of PM
10
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pathogenicity. Available results also suggest that inflammation is a key 
pathogenic and physiological feature for chronic respiratory diseases, such as 
asthma and chronic obstructive pulmonary disease (COPD), because the chronic 
and repeated inflammatory reactions may result in remodeling of the airway 
passages, leading to irreversible lung disease. Thus, inflammation may be 
involved in both acute and chronic effects.
Recent studies indicated that exposure to several types of particles could 
induce inflammation responses in humans(25’32). Study results have shown 
connections between exposure to concentrated ambient particles (CAPs) and 
altered pulmonary or systemic inflammatory markers, such as cytokines, 
chemokines, and adhesion molecules in healthy humans. Such observations 
suggested that exposures to the CAP particles may have an influence on 
endothelial and leukocyte activation, which is a key initial step in leukocyte 
recruitment, due to the critical functions of these soluble molecules in cell 
recruitment to atherosclerotic lesions and inflamed airways. In addition, more 
recent evidence (H. Geng et al, 2005) indicated that phagocytic activity of 
alveolar macrophages (AMs) was impaired by prolonged exposure to airborne 
fine particulate matter PM2.5 (particle size < 2.5 pm in aerodynamic diameter). 
Moreover, production of inflammatory factors, such as nitrogen oxide (NO), 
interleukin-8 (IL-8), and tumor necrosis factor - a  (TNF-a), was induced 
following PM2.5 exposure as well. Thus, these data well linked respiratory 
disorders, such as asthma morbidity, to PM2.5 exposure, due to the fact that AMs 
are specialized cells responsible for removing dusts / particles from the airways,
11
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and for eliminating microbial infections from the lung by granulocyte recruitment 
and immune activation with cytokine secretion from AMs.
Up to date, research efforts focusing on the pathogenicity of PM exposure 
have been made mainly in the fields of physiological and cellular mechanisms. 
The molecular mechanistic basis for the observed health effects induced by the 
bioactive particles is not yet completely understood, but starts receiving a great 
deal of attentions in the research field. This subject is likely to become more 
important as the research community focus more on the field of molecular 
epidemiology for the bioactive particulate induced health consequences. During 
the past few years, significant research progresses have been made on the 
mechanisms of PM - induced health effects, based on the novel advancement of 
cellular -  molecular research tools and the better understanding of underlying 
biological mechanisms. However, how to accurately evaluate and interpret the 
vast amount of resulting research data still remains as a problem. Thus, there have 
been a variety of important but yet unanswered questions, such as interpreting 
changes in protein products of gene activation, cellular receptor signaling, and the 
metabolic products of PM-associated compounds and the biological cascades they 
stimulate.
12
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Surface Receptors on Antigen Presenting Cells (APC)
Antigen presenting cells express a large variety of pattern recognition receptors 
(PRRs) on cell surface. These receptors enable the APC cells to detect and bind highly 
conserved infectious or endogenous ligands prior to phagocytosis activity, intracellular 
signal transduction, and altered biosynthesis and secretion of cytokines / chemokines, 
which can further direct the specific immune responses. There is a wide range of ligands, 
from either endogenous or exogenous origins, for APC surface PRRs, which may include 
proteins, polysaccharide, lipid, and nucleic acid. Due to the critical functions of the 
PRRs, pattern recognition of pathogen-associated molecules has become an important 
research topic in innate immunity. To date, the best known among the APC surface PRRs 
are the Toll-like receptors (TLR) and scavenger receptors (SR-A).
I. Toll-like receptors (TLR)
The identification and characterization of the Toll-like receptor (TLR) 
family is one of the most important discoveries in the field of innate immunity. 
Mammalian TLR proteins share sequence similarity with the Drosophila Toll 
protein, which was originally identified in the Drosophila embryo for its crucial 
role in defining the dorsal-ventral pattern formation. The cytoplasmic domains of 
Toll protein and the mammalian interleukin-1 receptor (IL-1R) were found to be 
homologous, leading to the hypothesis that similar receptors might be encoded in 
the mammalian genome. In 1997, the first human Toll protein was discovered, 
cloned, and termed “hToll” by Medzditov and Janeway(58). Since then, additional 
mammalian Toll-like proteins have been identified and been given the general
13
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term of “TLR”, and the very first “hToll” was renamed as “TLR-4”. Available 
studies have indicated that these receptors possess critical functions in detecting 
microbial infection, activating anti-microbial genes, as well as initiating and 
directing the adaptive immune responses. More recent studies have shown that 
TLRs play crucial roles that affect many aspects of the immune system, such as 
recognizing highly conserved microbial components or molecular features, 
engaging differential signaling pathways, guiding dendritic cells (DCs) 
maturation, and directing differentiation of T helper (TH) cells (2). Figure 1 - 4 
summarizes some of the vital roles for TLRs in the regulation of adaptive 
immunity.
PAMP or 
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Figure 1 - 4. Functions of Toll-like receptors (TLRs) in initiation and regulation of adaptive 
immunity. The innate immune system detects microbial infections by cell surface TLRs 
binding to highly conserved microbial ligands, leading to phagocytosis, APC activation, up- 
regulation of cell surface co-stimulatory molecules (CD80/86) and MHC-II complex. Thus, 
naive T- and B-lymphocytes are activated and antigen - specific TCR /BCR are generated. 
The TLR -  induced secretion of inflammatory cytokine and chemokines, such as IL-12, 
direct the immune response by guiding the maturation and differentiation of activated T cells 
towards T helper (TH) effector cells. Adapted from reference (2).
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Structurally, TLRs belong to the family of type I transmembrane 
receptors. All TLR family members possess an extracellular leucine-rich repeat 
(LRR) domain and an intracellular Toll/IL-1 receptor (TIR) domain. A diagram of 
TLR family members and their structure comparison with IL-1 receptors is shown 
in Figure 1 - 5. To date, at least ten TLR receptors have been identified in 
mammalian species, and each one of them appears to have distinct functions in 
innate immune recognition. During the past few years, a variety of TLR ligands 
have been identified, and results indicate that TLR ligands are highly diverse in 
structure and origin. Based on the available information, a proposed mechanism 
for specific ligand recognition by TLRs is shown in Figure 1 - 6 .  According to the 
identification and characterization studies, several common themes have been 
recognized regarding TLR functional mechanisms and their specific ligands. First, 
most TLR ligands are highly conserved microbial components or surface 
structures that can signal the presence and the nature of the infection. Second, 
most of the individual TLR receptors can recognize several ligands, and these 
ligands can be structurally related or unrelated. Third, for some TLRs, including 
TLR-4, ligand recognition and signal initiation require other accessory proteins to 
form a structural complex with the TLR. Finally, available data from binding 
studies indicate that direct binding with ligands is usually the first and critical step 
for mammalian TLR - mediated ligand recognize and signaling, suggesting that 
these receptors function as pattem-recognition receptors (PRR) (2,31 However, the 
actual and detailed mechanism of ligand recognition by TLRs remains unknown.
15
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Figure 1 - 5 .  Structural comparison between Toll-like receptor (TLR) family and 
Interleukin -  1 receptor (IL-1R) family. An intracellular TIR (Toll/IL-IR) domain is 
conserved for all members from both families. An unique extracellular leucine-rich 
repeat (LRR) domain is conserved for members in the TLR subfamily. Adapted 
from Reference(3).
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Figure 1 - 6 .  Specificities of pathogen-associated ligands for members of TLR 
family. Adapted from Reference(2).
As described earlier, human Toll-like receptor 4 (TLR-4) was the first 
discovered and characterized mammalian Toll protein, and it has been implicated 
in innate recognition and signaling of lipopolysaccharide (LPS). Surface 
expression of TLR-4 has been found on a variety of cell types. Macrophages and 
dendritic cells, the two major types of antigen presenting cells in the innate 
immune system, express TLR-4 on cell surface as well. Available studies 
indicated that recognition and signaling of LPS is mediated through TLR-4. 
However, the process of LPS recognition via TLR-4 is complicated, requiring 
several accessory proteins. The current understanding of this mechanism indicates 
that LPS-binding protein (LBP) is the first serum protein that binds to LPS, and 
then transfer LPS monomers to CD14 -4’5). CD14 is a glycosyl- 
phosphatidylinositol - linked membrane protein widely expressed on mononuclear 
cells, or, it can be secreted and expressed as a soluble serum protein as well.
CD14 has been well known as a high-affinity receptor for LPS (3). However, due
17
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to the fact that membrane CD 14 lacks a transmembrane domain, it is unlikely that 
membrane CD14 can transmit signals directly into the cells. MD-2, a small 
glycosylated protein that also lacks a transmembrane region, is another critical 
component of the LPS receptor complex. The expression of MD-2 is found on the 
surface of immune cells as well. Available data indicated that MD-2 was 
associated with the ectodomain of TLR-4, suggesting that it was included in the 
LPS signal complex formation(2). Even though the precise function of MD-2 is 
still unknown, previous studies have shown that MD-2 was required for efficient 
LPS recognition via TLR-4 (2,4\  Meanwhile, other studies have shown direct 
interactions between TLR-4 and LPS, however, such interactions still required 
involvements of CD14 and MD-2 for optimal LPS signaling (8\  Additionally, it 
has been found that CD14, TLR-4, and MD-2 could act in a simultaneous manner, 
when co-expressed in HEK293 cells, to bind radioactive labeled LPS (6).
However, the precise molecular mechanism of TLR-4 -  mediated recognition of 
LPS remains unclear, and has become one of the most challenging issues in Toll 
biology today.
II. Scavenger receptors
The scavenger receptors were first discovered in 1979, during the process 
of trying to understand how cholesterol from low-density lipoproteins (LDL) 
accumulates in macrophages in atherosclerotic plaques (11). Since then, a few 
different groups of scavenger receptors have been identified, including Class A 
collagenous scavenger receptors, Class B CD36 family, Drosophila Class C
18
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macrophage specific scavenger receptor named dSR-CI, mucin-like scavenger 
receptor family CD68/macrosialin, and an endothelial cell-specific scavenger 
receptor LOX-1 (Figure 1 - 7).
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Figure 1-7:  Different groups of scavenger receptors that have been identified to be 
involved in recognition of specific microbial ligands. Adapted from Reference{12).
The Class A scavenger receptors (SR-A) are mainly expressed in 
macrophages and related cells as membrane receptors. SR-As are able to 
recognize a variety of ligands, including chemically modified or altered 
molecules, and the modified lipoproteins that are pertinent to the development of 
vascular disease (13). The Class A SRs can be broadly classified as three different
19
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SR-A types, including type I, II, and III. Type III is a nonfunctional splice variant 
type. Another distant receptor member, MARCO, is also included in this class.
Type I and II SR-A receptors are multi-domain trimeric molecules 
composed of three identical protein chains, which preferentially bind acetyl-LDL. 
An N-terminal cytoplasmic domain and glycosylated fibrous coiled coil 
extracellular domains are conserved for members of both SR-A type I and II. In 
addition, both types have 23 (human) or 24 (bovine, rabbit, murine) uninterrupted 
Gly-X-Y tripeptide repeats that form a collagenous triple helix. There are five 
highly conserved basic amino acids among the C-terminal 22 amino acids of the 
collagenous-like domain. These basic amino acids have been found to have 
essential functions in binding with both oxidized LDL and acetyl-LDL n̂).
The concept of a “macrophage scavenger receptor” refers to a broad range 
of cell surface molecules involved in receptor-mediated endocytosis of selected 
polyanionic ligands. Other roles for some of these receptors have been identified, 
including phagocytosis of apoptotic cells and invading microbes, as well as 
functions in cell adhesion and host defense initiation (Figure 1 - 8). Two of the 
many themes that have been drawn from previous studies of macrophage SRs are 
particularly relevant to this dissertation. First, the ligand-binding properties of 
most macrophage SRs are quite broad and overlapping, therefore the biological 
specificity of these receptors has to be determined not only by ligand structure 
and its corresponding signal transduction pathways, but also by other 
considerations. These may include distribution and availability of the various SRs, 
their ability and specificity to interact with other receptors, and their relative
20
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affinities for the various ligands. Second, among the distinct classes of 
macrophage SRs, ligand binding usually occurs without conserved protein 
sequences. In order to better understand the mechanisms involved in individual 
SR’s broad and specific ligand recognition, and in the features shared by the 
unrelated molecules, it might require the examination of tertiary structures of the 
multiple SRs to solve the mystery.
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Figure 1 - 8. Biological functions identified for macrophage scavenger receptors. Adapted from 
Reference<13).
22
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
In 1991, Hampton and colleagues were the first to identify the involvement of SR- 
A in the binding of lipid A, the active component of LPS <14}. Their data showed that SR- 
A could mediate clearance and detoxification of plasma endotoxin. Expression of both 
type I and type II SR-A was also found to be up-regulated by intracerebral administration 
of LPS or cytokines (n\  Subsequently, the binding of lipoteichoic acid (LTA) of Gram- 
positive bacteria to SR-A was reported as w ell(15). Haworth tested the in vivo relevance 
of the data of Hampton and his coworkers, and the data generated from these in vivo 
studies were consistent with Hampton's in vitro w ork(16). SR-A deficient mice (SR-A /‘) 
were found to be more susceptible to LPS-induced shock after they had been primed by 
the mycobacterial vaccine Bacille Calmette Guerin (BCG) to activate their macrophages. 
The studies also showed that these results were accompanied by overproduction of 
cytokines, such as TNF- a  and IL-6, as well as other pro-inflammatory mediators, 
perhaps due to an imbalance between SR-A-dependent clearance of LPS and TLR-4- 
dependent pathways of secretory stimulation. However, the opposite findings have been 
reported as well, namely that SR-A_/' mice were more resistant to endotoxic shock(17). 
There are several possible explanations for the above contradictory results, and on-going 
studies are trying to solve the mystery.
Overall, the differential responses initiated by clearance of endogenous host 
ligands and exogenous microbial invaders are poorly understood, but remains as a key 
issue for immunological studies that try to understand the mechanisms of 
immunosuppression and autoimmunity, as well as immune activation. It has been well 
accepted that SR, as well as other pattern recognition receptors (PRR), such as TLRs,
23
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may function individually or cooperatively to play a critical role in defining and directing 
various adaptive immune responses following innate recognition via these PRRs.
Lipopolysaccharide has been well identified as a ligand for both SR-A and TLR-4 
receptors. However, knowledge regarding silica and PM receptors and their signaling 
pathways is still very limited, but has drawn significant attention in the research field. 
Therefore, it would be of interest to examine whether these two different PRRs could 
influence one another through a cross-talk mechanism as well as ligand-induced 
responses while cells are stimulated with LPS or bioactive particles. A detailed 
comparison of innate and adaptive immune activation also remains to be made.
24
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RESEARCH OBJECTIVES
The research objectives and corresponding specific aims of this dissertation are 
listed as follows.
Major Objective #1:
Evaluate the biological potency of synthetic lipid A compounds for potential 
vaccine and adjuvant development.
Specific Aims:
1. Develop a reproducible in vitro cell assay system using human monocytic cell 
lines U937 and MonoMac-6.
2. Evaluate biological potency of synthetic lipid A compounds with the above cell 
assay system by measuring quantitative cytokine secretion from activated human 
cell lines.
Major Objective #2:
Characterize specific involvement of Toll-like receptor-4 (TLR-4) in 
lipopolysaccharide (LPS) signaling pathways.
Specific Aims:
1. Perform inhibition study with the above cell assay system, using monoclonal anti- 
human-TLR-4 as receptor blocker.
25
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2. Verify and characterize human TLR-4 surface expression on U937 and 
MonoMac-6 cell lines using fluorescence conjugated TLR-4 specific monoclonal 
antibodies.
3. Generate fluorescence - conjugated lipopolysaccharide (LPS) direct-binding 
curves with U937 and MonoMac-6 cell lines.
4. Verify LPS-specific binding to the two human cell lines by detecting binding 
inhibition with non-labeled LPS and monoclonal anti-TLR-4 antibody, therefore 
further characterizing TLR-4 functions in LPS signaling and cell activating 
pathways.
Major Objective #3:
Test the hypothesis that both silica and urban particulates, as well as LPS, can up- 
regulate immune response by increasing the activity of antigen-presenting cells (APC) 
via TLR-4 and/or scavenger receptors (SR-A).
Specific Aims:
1. Verify surface expression of TLR-4 and scavenger receptors (SR-A) on murine 
bone marrow derived macrophage cells.
2. With a murine in vitro antigen presenting cell (APC) assay, perform inhibition 
studies using specific monoclonal antibodies as receptor blockers to determine the 
functions and cooperation mechanisms between TLR-4 and SR -A receptors for 
up-regulating APC response to bioactive particulates and to LPS.
26
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The experimental studies addressing the above objectives and specific aims are 
presented in Chapters 2, 3 and 4 of this dissertation. A summary of conclusions and 
future directions is presented in Chapter 5.
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CHAPTER 2
Biological potency evaluation of synthetic lipid A compounds with in vitro human
cell assay system
Introduction
As described in Chapter 1, LPS and its active lipid A component are potent 
stimulators of host immune systems. The lipid A portion of LPS is highly conserved in all 
Gram-negative bacteria, whereas the O-antigen portion is variable in LPS from different 
species of bacteria. Previous studies indicated that the pro-inflammatory effects of LPS 
were due to the biological activity of lipid A component, therefore, lipid A has the 
potential to act as an adjuvant for vaccine antigens. Moreover, due to its 
immunostimulating capability, lipid A may provide general protections against infections 
by functioning as a strong inducer of non-specific resistance (NSR). However, due to the 
highly endotoxic activities, the clinical and medicinal use of LPS and lipid A is very 
limited.
Because of the potentially beneficial and clinical use of lipid A, a considerable 
amount of research work has been performed focusing on LPS and its active lipid A 
component during the past two decades. One of the most significant achievements was 
conducted by Dr. Edgar Ribi and his colleagues at Ribi ImmunoChem Inc. (Hamilton, 
MT) in the early 80’s. They found that the toxicity of lipid A could be separated from its 
beneficial functions of inducing cytokines and other effector molecules, which were 
required for adjuvant activities, by modifying lipid A structure. Based on their discovery, 
the natural product of monophosphoryl lipid A (MPL™ Adjuvant) was derived from LPS, 
and it has been included in several vaccine products for on-going clinical or pre-clinical
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testing. For example, it is currently under consideration for regulatory approval as an 
adjuvant in a prophylactic hepatitis B virus vaccine in the United States.
Monophosphoryl lipid A (Figure 2 -1 ) is an attenuated derivative of LPS from 
Salmonella minnesota R595. Isolated from its parent molecule LPS, MPL is an immuno- 
active lipid A fraction with only one signal phosphate group. Available research data 
indicate that MPL has potent adjuvant and immunostimulating activities, but does not 
posses the many endotoxic properties from its parent molecule LPS (30’31). Adjuvant 
evaluation studies performed in several clinical or pre-clinical trials have shown that 
MPL™ Adjuvant is immunologically potent with clinical safety when administrated to 
humans at its active doses, measured by human cytokine induction and cytotoxic T cell 
activation, e tc (28' 30,31(
Based on the knowledge and experience with MPL Adjuvant, scientists at Corixa 
Corporation have developed a library of novel synthetic glycolipids, the aminoalkyl 
glucosaminide 4-phosphates (AGPs). These molecules are lipid A mimetics structurally 
related to the major hexaacyl component (Figure 2 - 1 )  present in the low toxicity 3-0- 
deacylated monophosphoryl lipid A (MPL™Adjuvant) derived from Salmonella, 
minnesota R595 lipid A. With the general structure as shown in Figure 2 - 2, the AGPs 
are synthetic lipid A compounds in which the reducing sugar in Figure 2 -1  has been 
replaced with an aminoalkyl aglycon unit ('1\  The structures of a few representative AGP 
compounds that will be tested in this project are shown in Figure 2 - 3 .
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Figure 2 - 1. Structure of the major hexa-acyl component of monophosphoryl 
lipid A. Adapted from Reference (7).
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Figure 2 - 2. General structure of aminoalkyl glucosaminide 4-phosphates (AGPs).
(1)Adapted from Reference 1 .
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Figure 2-3. Chemical structures of AGP compounds: RC-522, RC-524, RC-527, RC-529, 
RC-545, and RC-590.
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In order to develop and select compounds as potential novel clinical products, 
research work has been performed at Corixa Corporation focusing on the functional 
mechanism of MPL and AGP compounds. Biological potency of AGP compounds was 
also evaluated with different in vitro or in vivo models. After synthesis, AGP compounds 
may be formulated in either of two ways. For the so-called “AF” formulation, AGP tri­
ethyl amine (TEA) salt is dissolved in dipalmitoyl phosphatidylcholine (DPPC) with 
water and sonicated for suspension. For the “TEOA” formulation, AGP TEA salt is 
dissolved in 0.2% tri-ethanolamine (TEOA) with water. Cytokine-inducing potency of 
AGP compounds with both formulations have been evaluated in a human setting with 
human whole blood as well as human PBMC cultures (11). The induction of the innate 
immunity by various AGPs was also examined in two distinct murine models (T). Data 
obtained from the above studies strongly suggested that Toll-like receptor 4 (TLR-4) was 
required for signal transduction and cell activation induced by MPL or AGP compounds 
(13‘15), and the AGP fatty acyl chain length had significant effects on the stimulatory 
capacity of these compounds (7\  However, no in vitro cell assay system is available at 
this stage for reproducible evaluation of AGP biological potency. Therefore, one major 
objective of this study was to develop the basic parameters of a reproducible in vitro cell 
culture system using human monocytic cell lines MonoMac-6 and U937 for synthetic 
lipid A compound potency evaluation.
In vitro cell assays using human cell lines or cloned cell lines provide a 
predictable and accurate means for assessing research compounds. Although human 
whole blood and human PBMC cultures have been used as test systems for adjuvant and 
synthetic lipid A compound evaluation, whole blood contains polymorphonuclear as well
32
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
as mononuclear white blood cells. Meanwhile, donor-to-donor variation adds a measure 
of unpredictability to the results. A predictable in vitro human cell assay system can be 
applied to better characterize and compare the activation of mononuclear cells present in 
human whole blood by stimulants. Such a system also could be adapted for development 
of potency assays for synthetic lipid A mimetic, such as AGPs.
Derived from a human histocytic lymphoma, the U937 cell line may serve as a 
study model for monocytic differentiation. Because of its well defined adhesive 
properties, this cell line, with the basic phenotype corresponding to normal monoblasts 
(3), has been frequently applied in assessing monocytic cell adhesion to human umbilical 
vein endothelial cell (HUVEC) monolayers <2). U937 cells may be rendered the 
phenotypic properties similar to normal monocytes and macrophages by proper induction 
of differentiation. Previous studies reported that the inducers for such differentiation 
might include phorbol 12-myristate 13-acetate (PMA), cholecalciferol (Vitamin D 3), 
retinoic acid, or a cocktail of interferon gamma (IFN-y), IL-6, and GM-CSF(3,4|.
MonoMac-6, on the other hand, is another human monocytic cell line that has 
been frequently used to analyze the behavior of monocytes in vitro (7’8). Such utilization 
of MonoMac-6 cells is mainly due to its derivation from a human monoblastoma(5,6), and 
its mature monocytic properties, including CD 14 antigen expression, phagocytosis 
activity, and the ability of cytokine secretion when stimulated. Available studies 
indicated that MonoMac-6 cells appeared to be arrested at a more mature stage of 
monocyte differentiation compared to U937 cells, whose differentiation was found to be 
associated with growth cessation in the G0/G1 phase of the cell cycle (3’4>.
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Based on the available knowledge, the above two human cell lines were selected 
to develop a reproducible in vitro cell culture system for lipid A compound and adjuvant 
evaluation in this study.
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Materials and Methods
Cell Lines and Culture Medium
U937 cells
U937 cells were obtained from American Type Culture Collection (ATCC, Manassas, 
Virginia). Cells were grown in RPM I1640 (Sigma) with 2 g/L sodium bicarbonate and 2 
mM glutamine (Sigma) supplemented with 10% heat inactivated fetal bovine serum 
(FBS, HyClone), 100 pg/ml gentamicin (Sigma) and 10 mM HEPES buffer (Sigma).
MonoMac-6 cells
Mono Mac 6 cells were obtained from Deutsche Cell Bank (Germany), and were grown 
in RPMI 1640 (Sigma) plus 10% heat inactivated fetal bovine serum (HyClone), 2 mM 
L-glutamine, 10.0 units/ml Penicillin, 10.0 pg/ml Streptomycin (Penicillin/Streptomycin, 
Sigma), 0.2x non-essential amino acid solution (L-Alanine, L-Asparagine, L-Aspartic 
acid, L-Glutamic acid, Glycine, L-Proline, and L-Serine. Sigma), 150 pg/ml oxaloacetate, 
50 pg/ml pyruvate, and 8.2 pg/ml bovine insulin (OPI medium supplement, Sigma).
Culture conditions and Cell bank
Cells were grown in respective culture media in T75 culture flasks in a 37 °C CCF 
incubator. Neither cell line was adherent; therefore, after harvesting by centrifugation, 
cells were resuspended in fetal bovine serum with 6% dimethyl sulphoxide (DMSO) at 
2.0 x 106 cells/ml, and frozen at - 70°C in 1.0 ml/vial aliquots.
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AGP compounds and cell stimulants
MPL™ Adjuvant and AGP compounds used in this study were kindly provided by Corixa 
Corporation (Montana Facility). The AGP library for potency evaluation included 
RC524, RC526, RC527, RC529, RC534, RC545, and RC590.
Phorbol 12-myristate 13-acetate (PMA), phytohaemagluttinin (PHA), cholecalciferol 
sulfate (Vitamin D3), and E. coli DNA (from E. coli serotype 055:B5) were obtained 
from Sigma.
LPS was applied in this study as a positive control for cell activation measurement. 
Unlabeled LPS preparation was obtained from Sigma (E. coli serotype 0111:B4), and 
fluorescence conjugated (Alexa Fluor 488) LPS was purchased from Molecular Probes. 
For the purpose of further appropriate inhibition tests, both labeled and unlabeled LPS 
were from the same E. coli serotypes (0111:B4), and had gone through the same 
purification procedures. The two LPS preparations were both chromatographically 
purified by gel filtration after an initial phenol extraction.
Cell culture preparation for in vitro assay
Fresh cell cultures were prepared weekly for each in vitro cell assay. For each 
preparation, one vial containing 2.0 x 106 cells in 1.0 ml of each cell stock, was quickly 
thawed in 37 °C water bath, added to 9.0 ml of respective culture medium and 
centrifuged for 5 minutes at 1500 rpm in order to remove DMSO. After centrifugation, 
supernatant was removed, and the cell pellet was resuspended in 35 ml of pre-warmed 
culture medium and transferred to a T75 culture flask. Cells were incubated in a 37 °C 
CO2 incubator for three days, then fed once with 15 ml fresh medium, and incubated for 
another 24 hours. After overnight incubation, cell culture was ready for assay.
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Cell culture pre-stimulation
Cells were harvested from a T75 culture flask, transferred to a 50 ml centrifuge tube, and 
centrifuged at 1500 rpm for 5 minutes. After removing supernatant, cells were 
resuspended in 5.0 ml of fresh culture medium, counted, and cell concentration was 
adjusted to 2.5 x 10 6 cells/ml. Cells then were distributed to 96-well cell culture plate at 
100 pl/well with 2.5 x 105 cells/well.
Phorbol 12-myristate 13-acetate (PMA, SIGMA catalog #P-8139) powder was dissolved 
in dimethyl sulphoxide (DMSO) to reach a concentration at 1.0 mg/ml, aliquot and stored 
at -70 °C as stocks. For cell pretreatment, the PMA stock was diluted in respective culture 
medium to various concentrations, and added to the cell cultures at 100 pl/well. Control 
wells received fresh culture medium only. The plate was then incubated in a 37 °C CO2 
incubator. At the end of each different “pre-stimulation” period, cells were stimulated 
with LPS at 10 ng/mL for 3 hours, and cell activation was measured by quantitative 
cytokine secretion with Luminex 100™ Analyzer (Luminex Corporation, Austin, TX). 
The most appropriate pretreatment (the combination of PMA concentration and 
incubation time period) was identified based on the highest cytokine data.
Human in vitro cell assay
With the appropriate cell pre-stimulation identified from the previous step, stock 
solutions of various stimulants were diluted in respective fresh culture medium and added 
to the pretreated cells at 100 pL/well for cell stimulation. In order to reach the desired 
final stimulant concentration in each well, a 3-fold concentration of each stimulant had to 
be prepared for addition to the plate. After stimulant addition, the 96-well culture plate 
was incubated in the 37 °C CO2 incubator for various time periods in order to determine
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an appropriate stimulation period for each cell line. At the end of incubation, the plate 
was centrifuged at 1100 rpm for 3 minutes, and 200 pL supernatant was harvested from 
each well. Cell activation was measured by quantitative cytokine secretion with a 
Luminex 100 Analyzer, and the most appropriate stimulation time period for each cell 
line was identified based on the highest cytokine data.
Evaluation of AGP biological potency with the developed human cell assay system 
Based on the cytokine data obtained from the previous steps, a Standard Operational 
Procedure (SOP) was developed for an in vitro cell assay system using human U937 and 
MonoMac-6 cells (see the section of “Discussion & Conclusions”). Biological potency of 
AGP compounds, including RC522, RC524, RC527, RC529, RC545, and RC590, was 
evaluated following the obtained SOP by measuring quantitative cytokine secretion from 
the cells stimulated with various AGP compounds.
Measurement of human cytokine release
Cell culture samples collected from the previous step were thawed at room temperature, 
and Luminex 100 Analyzer was applied for the measurement of human cytokines. A 
Fluorokine MAP Human Base Kit (R&D systems Catalog #LU000) was applied for 
quantitation of multiple cytokines released from every single cell sample. A combination 
of five human cytokines, including TNF- a , IL-ip,. IL-6, IL-8, and IL-10, was measured 
due to previous data from our laboratory that suggested such a cytokine combination 
could be simultaneously quantified using the above system without further sample 
dilutions.
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For experimental operation, standards provided by test kit were included in each 
measurement. The median value of relative fluorescence units (RFU) was collected from 
all samples with the Luminex machine and its installed “IS” software. A set of standard 
curves was generated, one curve for each cytokine, based on the RFU values of the 
standards and their concentrations with a four parameter logistic (4-PL) curve fit (RFU 
values vs. Standard pg/ml values). Multiple secreted cytokine values (pg/ml) of each test 
sample were calculated based on sample RFU value and the available standard curve for 
each cytokine.
Statistics
For the stimulant concentration -  dependent cytokine data, a one -  way analysis of 
variance (ANOVA) was applied for data analysis with a post hoc comparison using 
Dunnett test. Other analysis included one sample, one -  tailed unpaired t test, Student -  
Newman -  Keuls test, and Bonferroni test. Sample size for each experiment is available 
in the figure legends.
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Results 
PMA concentration for pre-stimulation
A wide concentration range of PMA, from 5 ng/ml to 0.005 ng/ml, was tested in order to 
determine the appropriate cell pretreatment. PMA at various concentrations was added to 
the cells and co-incubated with LPS at 10 ng/ml for 3 hours in a 37 °C CO2 incubator. 
Samples were harvested after incubation and cytokine secretion was measured. Both 
MonoMac-6 and U937 cells pretreated with PMA at 5.0 or 2.5 ng/ml had the highest 
levels of cytokine release. Cytokine data obtained from cells pre-stimulated with lower 
PMA concentrations were close to background levels obtained from cells without 
pretreatment (Figure 2 - 4). Therefore, PMA concentration at 2.5 ng/ml was selected for 
cell pre-stimulation.
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Figure 2 - 4 .  Concentrations of PMA for cell pretreatment.
PMA was diluted in respective culture medium to 5, 2.5, 0.5, 0.25, 0.05, 0.025, 0.005, 
and 0 ng/ml. PMA was then added to MonoMac-6 and U937 cells and co-incubated with 
LPS (E. coli serotype 0111:B4) at 10.0 ng/ml for 3 hours in a 37 °C CO2 incubator. 
Samples were harvested and cytokine secretion was measured. Upper panel: TNF-a 
(filled bars) and IL-6 (empty bars) secretion (pg/ml) from MonoMac-6 cells; Lower 
panel: IL-8 secretion (pg/ml) from U937 cells. Data are shown as means + STDEV, n =
5. Statistical analysis by 1 -  factor ANOVA followed by Newman-Keuls multiple 
comparison to multiple controls. (*) = statistical significance atp<  0.05.
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Time period for PMA pretreatment
Various time periods of pretreatment were tested with PMA on both U937 and 
MonoMac-6 cell lines. The two cell lines had different requirements for a pre-stimulation 
period. For MonoMac-6, cells pretreated for 3 hours had the most cytokine secretion, 
whereas 24 hour pretreatment caused the lowest cell response (Figure 2 - 5  and Figure 2 - 
6). On the other hand, overnight pre-stimulation was required by U937 cells for 
activation (Figure 2 - 7). Flow cytometry data from our laboratory indicated that overdose 
(over 5 ng/ml) or over-exposure (overnight incubation) with PMA could cause cell death 
due to PMA toxicity (data not shown).
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Figure 2 - 5. Time periods for PMA pretreatment (MonoMac-6 cells).
MonoMac-6 cells were pretreated with PMA (2.5 ng/ml) for 0, 3, and 24 hours. Cytokine 
secretion (IL-1 beta and IL-6) was measured after LPS (£. coli serotype 0111:B4,1.0 
ng/ml) stimulation for 22 hours. Data are shown as means + STDEV, n = 4. Statistical 
analysis by two - way ANOVA followed by post test of Bonferroni. (*) = statistical 
significance atp  < 0.05.
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Figure 2 - 6. Time periods for PMA pretreatment (MonoMac-6 cells).
MonoMac-6 cells were pretreated with PMA (2.5 ng/ml) for 0, 3, and 24 hours. Cytokine 
secretion (IL-8 and IL-10) was measured after LPS (E. coli serotype 0111:B4, 1.0 ng/ml) 
stimulation for 22 hours. Data are shown as means + STDEV, n = 4. Statistical analysis 
by two - way ANOVA followed by post test of Bonferroni. (*) = statistical significance 
at p < 0.05.
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Figure 2 - 7. Time periods for PMA pretreatment (U937 cells).
U937 cells were pretreated with PMA (2.5 ng/ml) for 0, 3, and 24 hours. Cytokine 
secretion (IL-lp and IL-8) was measured after LPS (E. coli serotype 0111:B4,1.0 ng/ml) 
stimulation for 22 hours. Data are shown as means + STDEV, n = 4. Statistical analysis 
by two - way ANOVA followed by post test of Bonferroni. (*) = statistical significance 
atp<  0.05.
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Time period for cell stimulation
With proper respective PMA pretreatment, MonoMac-6 and U937 cells were stimulated 
with LPS, MPL ™ adjuvant, and AGPs for various time periods in order to determine an 
appropriate stimulation period for each cell line. MonoMac-6 released more TNF-alpha 
with 5 hour stimulation, but more IL-6, IL-8, IL-10, and IL-1 beta were released with 22 
hour stimulation (Figure 2 - 8). Similar observations were obtained with U937 cells 
(Figure 2 - 9), therefore, 22 hours incubation was selected for both cell lines as an 
optimum stimulation period.
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Figure 2 - 8. Time periods for cell stimulation (MonoMac-6 cells).
MonoMac-6 cells were pretreated with PMA (2.5 ng/ml) for 3 hours, and stimulated with AF formulated 
RC-522 for 5 or 22 hours. TNF-a and IL-6 secretion was measured with Luminex 100 Analyzer. Top 
panel: AF-RC522 at concentrations of 1000, 100,10, and 1 ng/ml; Data are shown as means + STDEV, n = 
3. Statistical analysis by two - way ANOVA followed by post test of Bonferroni. (*) = statistical 
significance at p < 0.05. Middle and bottom panels: AF-RC522 at 10000 ng/ml. Data are shown as means + 
STDEV, n = 3. Statistical analysis was performed with one -  tailed unpaired t — test. (*) = statistical 
significance at p < 0.05.
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Figure 2 - 9. Time periods for cell stimulation (IJ937 cells).
U937 cells were pretreated with PMA (2.5 ng/ml) overnight, and stimulated with 0.2% TEOA 
formulated RC-527 for 6  or 22 hours. TNF-a and IL- 6  secretion was measured with Luminex 100 
Analyzer. Top panel: U937 cells were stimulated with TEOA-RC527 at 100, 10,1, and 0.1 ng/ml; 
Data are shown as means + STDEV, n = 3. Statistical analysis by two - way ANOVA followed 
by post test of Bonferroni shows no significant difference (p < 0.05) between groups of 6  and 22 
hours for TNF-a production, but shows significant difference for IL-6  production. (*) = statistical 
significance at p  < 0.05. Bottom panel: U937 cells were stimulated with TEOA-RC527 at 100 
ng/ml. Data are shown as means + STDEV, n = 3. Statistical analysis was performed with one -  
tailed unpaired t -  test. (*) = statistical significance at p  < 0.05.
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Cytokine secretion in response to lipopolysaccharide (LPS) stimulation
LPS was applied as a positive control stimulant in this study. A combination of five 
human cytokines was measured from each sample with a Luminex 100 Analyzer, 
including TNF-alpha, IL-1 beta, IL-6, IL-8, and IL-10. Both cell lines had a dose 
response to LPS stimulation, but within a different LPS concentration range. MonoMac-6 
cells exhibited dose responses within a LPS concentration range from 10 ng/ml to pg/ml 
levels (Figure 2 -10), whereas U937 required a higher concentration range starting from 
50 ng/ml for activation (Figure 2 -11 ). PHA (Sigma), E. coli DNA (Sigma), and MPL 
(Corixa) were also tested with MonoMac-6 cells, and dose response was obtained with 
each stimulant (Figure 2-12).
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Figure 2 -10. Cytokine secretion from activated MonoMac-6 cells.
Cytokine secretion (IL-ip and IL-10) from MonoMac-6 cells stimulated with LPS at 5,
2.5,1.25,0.625, 0.312, 0.156, 0.078, 0.039 ng/ml. Cells were pretreated with PMA (2.5 
ng/ml) for 3 hours, and stimulated with LPS (.E. coli serotype 0111:B4) for 22 hours. 
Data are shown as means ± STDEV, n = 5. Statistical analysis was performed with one -  
way ANOVA followed by Dunnett’s multiple comparison to a single control group. All 
cytokine data obtained from LPS stimulation at concentrations above 0.156 ng/mL 
showed significant difference ip < 0.05) over control value obtained from group treated 
with medium only.
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Figure 2 -11. Cytokine secretion from activated U937 cells.
Cytokine secretion from human U937 cells stimulated with LPS at: 50, 40, 30, 20, 15, 10, 7.5,
5.0, 2.5,1.25, 0.625, 0.312, 0.16, 0 ng/ml. Cells were pretreated with PMA (2.5 ng/ml) 
overnight, then stimulated with LPS (E. coli serotype 0111:B4) for 22 hours. Data are shown as 
means + STDEV, n = 5. Statistical analysis was performed with one -  way ANOVA followed by 
Dunnett’s multiple comparison to a single control group. All cytokine data obtained from LPS 
stimulation at concentrations above 2.5 ng/mL showed significant difference (p < 0.05) over 
control value obtained from group treated with medium only.
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Figure 2-12. MonoMac-6 cell activation with LPS, E. coli DNA, PHA, and MPL stimulation.
TNF-a and IL-6 secretion from human MonoMac-6 cells stimulated with LPS, E. coli DNA, PHA, and 
MPL™ Adjuvant. Concentrations o f all stimulants: 10,5, 2.5,1.25, 0.625, 0.312, 0.156, and 0.0 ng/ml.
Data are shown as means + STDEV, n = 5. Statistical analysis was performed with one -  way ANOVA 
followed by Dunnett’s multiple comparison to a single control group. All cytokine data obtained from cell 
activation with stimulant’s concentrations above 0.312 ng/mL showed significant difference (p < 0.05) over 
control values obtained from groups treated with medium only.
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Cytokine secretion in response to AGP stimulation
AGP compounds, RC522, RC524, RC527, RC529, RC545, RC590 in AF formulation, 
and RC524, RC527, RC545, RC590 in 0.2% TEOA formulation, were tested for potency 
evaluation using the above in vitro cell assay systems. Levels of secreted cytokines were 
measured with a Luminex 100 Analyzer. Both cell lines exhibited dose responses to AGP 
stimulations, and typical dose response curves obtained from individual experiments are 
shown in Figure 2 -1 3 . For both AF and 0.2% TEOA formulated AGPs, RC-522 and 
RC-527 were the most potent compounds, whereas RC-524 and RC-545 had less but 
s i m i l ar potency. RC-529 was the least potent AGP compound among those tested (Figure 
2 -14 and Figure 2 -15).
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Figure 2 -13. Dose response curves obtained from MonoMac-6 and U937 cells 
stimulated with AF or 0.2% TEOA-formulated AGPs.
Top panel: MonoMac-6 cells stimulated with AF-RC522 at 1000, 100.10, and 1 ng/ml; 
Middle panel: MonoMac-6 cells stimulated with AF-RC529 at 10000,1000, 100,10, and 
1 ng/ml; Bottom panel: U937 cells stimulated with TEOA-RC527 at 100, 10, 1, and 0.1 
ng/ml.
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Figure 2 -14. Potency evaluation of AF formulated AGPs.
MonoMac-6 cells were pretreated with PMA at 2.5 ng/ml for 3 hours, and stimulated with AF-AGPs at 100 
ng/ml for 22 hours. TNF-alpha, IL-6, and IL -ip  were measured. Data are shown as means + STDEV, n = 5. 
Statistical analysis was performed by 1 — factor ANOVA followed by Newman -  Keuls multiple 
comparison to multiple controls. (*) = statistical significance at p  < 0.05.
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Figure 2 -15. Potency evaluation of AGPs in 0.2% TEOA formulation.
MonoMac-6 cells were pretreated the PMA (2.5 ng/ml) for 3 hours, and stimulated with 
TEOA-AGPs at 5.0 pg/ml for 22 hours. Cytokine secretion of TNF-alpha, IL-6 (top 
panel), and IL-ip (bottom panel) was measured with Luminex Analyzer. Data are shown 
as means ± STDEV, n = 5. Statistical analysis was performed by 1 -  factor ANOVA 
followed by Newman -  Keuls multiple comparison to multiple controls. (*) = statistical 
significance at p < 0.05.
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Effect of co-incubation with PMA
PMA co-incubation during the stimulation period was tested. MonoMac-6 cells were 
pretreated with PMA at 2.5 ng/ml for 3 hours. At the end of the pretreatment period, the 
assay was either processed with addition of stimulants directly to the cells, or 200 pi 
culture supernatants were removed from each well, and stimulants were diluted in fresh 
culture medium and added to the wells for stimulation without PMA. All samples were 
harvested after 22 hours incubation, and cytokine release was measured using the 
Luminex system. PMA presence during the cell stimulation period significantly increased 
the secretion of TNF-a, IL-lp, and IL-6 (Figure 2 -16). However, compared to control 
samples that were treated with culture medium only, PMA alone did not increase 
cytokine background.
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Figure 2 -16. Effect of PMA co-stimulation with LPS and AGPs on cytokine secretion.
MonoMac-6 cells were pretreated with PMA (2.5 ng/ml) for 3 hours, then stimulated with LPS or AGPs 
(TEOA) with or without continued PMA presence. AGP concentration: 5.0 pg/ml; LPS concentration: 10 
ng/ml. Data are shown as means + STDEV, n = 3. Statistical analysis was performed with one -  tailed 
unpaired t -  test. For samples stimulated with AGPs or LPS, all cytokine data obtained with continued 
PMA presence (solid bars) showed significant difference {p < 0.05) over data obtained without continued 
PMA presence (empty bars). However, there is no significant increase of cytokine production from samples 
treated with PMA only, as compared to samples treated with medium only.
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Comparison of biological functions between fluorescence-conjugated and non­
conjugated LPS
FITC-LPS was tested for binding to the surface of MonoMac-6 cells. Biological activity 
of FITC labeled LPS was tested and compared with unlabeled LPS. Due to possible loss 
or change of LPS biological functions during labeling and purification procedures, or due 
to serotypes, the labeled and unlabeled LPS preparations for comparison study were from 
the same E. coli serotype (E. coli 0111:B4, SIGMA catalog number L3012 and F3665), 
and were both purified by a two-step process of gel filtration after an initial phenol 
extraction.
Cytokine data obtained using the above cell culture system showed a typical dose 
response from MonoMac-6 cells stimulated with FITC-LPS. However, FITC-labeled LPS 
had about 20 - 25% reduction of biological functions compared with unlabeled LPS 
(Figure 2 -17). A comparison study was also performed between Alexa - conjugated LPS 
(Molecular Probes) and unlabeled LPS from the same E. coli serotype 055 :B5, and 
similar data were obtained (data not shown). The FITC-LPS obtained from SIGMA 
contained 3 pg of FITC in every milligram of LPS, so the percentage of FITC in this LPS 
preparation was 0.3%, which could not account for the 20% loss of biological activity. 
Therefore, this comparison study suggested that a minor loss of biological activity could 
result from the FITC conjugation procedure.
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Figure 2 -17. Comparison of biological activities between FITC - conjugated LPS and 
unlabeled LPS from E. coli serotype 0111:B4.
MonoMac-6 cells were pretreated with PMA (2.5 ng/ml) for 3 hours, then stimulated with FITC 
conjugated LPS (empty triangles) or unlabeled LPS (filled squares) for 22 hours. Cytokine 
secretion (TNF-a, IL-6, and IL-1P) was measured for biological activity comparison. Data are 
shown as means + STDEV, n = 3. Statistical analysis by two - way ANOVA followed by post test 
of Bonferroni. (*) = statistical significance at p  < 0.05.
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Discussion and Conclusions
Monocytes are one of the essential components of the immune response system 
due to their activities of phagocytosis, antigen presentation, and cytokine secretion. On 
the other hand, the involvement of monocytes in various disease pathologies has been 
known as well. For example, the severe clinical syndromes, septicemia and shock, are 
due to the augmented monocyte activation in response to LPS. The LPS -  induced cell 
activation leads to extensive cytokine productions, such as IL-1, IL-6, and tumor necrosis 
factor - alpha (TNF-a), which are responsible for initiating the disease states (1\  Hence, 
representative monocytic cell lines could be applied as appropriate research tools for 
detailed analysis of monocyte functions in either physiological or pathological 
mechanisms.
In the current study, an in vitro cell assay system was developed with human 
monocytic cell lines MonoMac-6 and U937. Both cell lines could be activated by phorbol 
12-myristate 13-acetate (PMA) to respond to LPS, MPL™ Adjuvant, and AGP 
compounds. Responses were measured by quantitative cytokine secretion. Potency of two 
formulations of AGP compounds was evaluated with this cell assay system. Biological 
functions of fluorescence conjugated and unlabeled LPS were tested and compared as 
well. Based on our data, MonoMac-6 cell line is recommended for further cell assay 
development and application.
Cell pretreatment
Effect of pretreatment on cell response was previously tested with human cell 
lines THP-1, K562, and U937 in our laboratory. Because adherence has been considered
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a marker of differentiation for monocytic cells(4,16,17), 4-beta-phorbol-12-myristate 13- 
acetate (PMA), phytohaemagluttinin (PHA), and cholecalciferol sulfate (Vitamin D3) 
were applied to pretreat the above cell lines for various time periods in order to determine 
if these non-adherent cells could be rendered adherent. THP-1 cells were rendered 
adherent after 24 hour pretreatment only with PMA, but neither U937 nor K562 could be 
induced to adhere to the culture plate by any of the above pretreatments. Previous data 
also had indicated that without proper pretreatment, neither THP-1 nor K562 cells could 
be activated by MPL or LPS as expected, suggesting that pre-stimulation is required for 
cell activation. Adherence did not correlate with activation by MPL in THP-1 cells (data 
not shown).
The pretreatment effect of PMA, PHA, and vitamin D3 on THP-1 cell activation 
was investigated and compared early in our laboratory. THP-1 cells were pretreated 
overnight with PMA at 5 ng/ml, PHA at 10 pg/ml, or Vitamin D3 at 2 pg/ml. After 
pretreatment, cells were stimulated with MPL at 20 pg/ml for 22 hours. Cytokine (IL-8) 
secretion was then measured with R&D Human IL-8 ELISA kit. After PMA pretreatment 
and MPL stimulation, IL-8 secretion from THP-1 cells was 6,600 pg/ml, whereas with 
PHA or Vitamin D3 pretreatment, IL-8 secretion from THP-1 cells was close to the un­
pretreated sample levels (both around 800 pg/ml). Based on these available data, PMA 
was selected for further investigations in our current study.
Previous data from Merck Research Laboratories indicated that addition of LPS at 
10 ng/ml to MonoMac-6 cells induced very little production of TNF-a (57). However, co­
incubation of LPS with PMA significantly increased TNF-a secretion, whereas PMA 
alone is inactive (5), suggesting PMA is required for the completion of TNF-a precursor
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processing and secretion in LPS-treated MonoMac-6 cells. Our development data are in 
agreement with these findings, and the current study extended these findings by testing 
both U937 and MonoMac-6 cell lines. PMA pretreatment was required for both cell lines 
to respond to UPS, MPL, and AGPs. Co-stimulation of PMA with stimulants was 
significant for cell responses, whereas PMA alone did not trigger cell activation.
Structural requirements for biological potency of AGP compounds
Based on the discovery and development work of Ribi ImmunoChem with MPL 
Adjuvant, a library of novel synthetic glycolipids known chemically as co -aminoalkyl 2- 
amino-2-deoxy-4-phosphono-(3-D-glucopyranosides (aminoalkyl glucosaminide 4- 
phosphates, or AGPs) was developed by scientists at Corixa Corporation. Since then, a 
considerable number of studies have been conducted at Corixa Corporation to investigate 
receptor mediated signaling pathways employed by AGP compounds. Using receptor 
negative cell lines transfected with TLR-4, the cells were stimulated with AGP 
compounds, and cell activation was measured by cytokine secretion. Results obtained 
from the above study strongly suggested that a combination of TLR-4 and MD-2 was 
required by AGPs for signal transduction (9\  Furthermore, potency evaluation studies 
indicated that the secondary fatty acyl chain length of AGPs played an important role in 
determining compound biological potency(7’31). AGP compounds that posses 10 carbon 
secondary acyl chains appeared to be the most potent TLR-4 agonists. For example, 
compound RC-524 with CIO acyl groups was approximately 5 times more potent than 
RC-529 (C14 acyl groups), measured by TNF-a and IL-ip secretion from AGP -  treated 
human whole blood in vitro {7\
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Similar studies were performed using in vitro human PBMC culture systems, and 
data again indicated that AGP compounds carrying 9,10,11, or 12 carbons in their 
secondary fatty acids were generally 20 to 30-fold more potent compared to compounds 
with 6, 7, or 8 carbons in their secondary positions. RC-527, another AGP compound that 
carries ten-carbon fatty acids in all three secondary positions, showed the highest 
biological potency in this study(7). Furthermore, two in vivo infectious disease models, 
using influenza virus or Listeria monocytogenes, were applied to investigate the 
relationship between AGP protective capability (non-specific resistance) and its chemical 
structure. Results obtained from this in vivo study were very similar to the above in vitro 
findings, indicating that AGPs carrying 9 - 1 2  carbons at their secondary positions 
provided the most effective protection against infection in mice, compared to compounds 
with either short ( 6 - 8  carbons) or long (14 carbons) secondary fatty acid chains.
Data generated from our current in vitro cell assay study are in agreement with the 
previous findings. Both AF formulated and 0.2% TEOA formulated AGPs showed 
similar biological potency patterns when evaluated with the developed in vitro cell assay. 
Dose responses were obtained from both cell lines by stimulation of AGPs with either 
formulation (Figure 2 -13). Compound RC-527, both AF and 0.2% TEOA formulated, 
appeared to be the most potent AGP, followed by compound RC-522 (Figure 2 - 1 4  and 2 
- 15). Compound RC-524 and RC-545 exhibited less but similar potency. Again, 
compound RC-529, which has 14 carbon acyl chains at all three secondary positions, was 
the least potent compound. Our data indicated that in vitro samples stimulated with RC- 
529 secreted about the same amount of cytokines compared to samples treated with PMA 
only. Based upon our cytokine data, RC-527 was 15, 17, and 62-fold more potent
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compared to RC-529 when measured by TNF-a, IL-ip, and IL-6 secretion, respectively. 
Another potent AGP RC-522 appeared to be 18, 16, and 45-fold more potent compared to 
RC-529, when measured with the above three cytokines as well.
Data obtained from the current and previous studies indicated that certain 
structural parameters had significant effects on AGP biological activity. Such information 
regarding chemical structure and biological potency would greatly help identify key 
structural characteristics that are responsible for the high immune potency. Chemical 
structure is the key component that could directly impact compound solubility in aqueous 
solutions, as well as on its stability by increasing resistance to enzymatic or chemical 
degradation. Different secondary fatty acid chain length of AGPs would affect the acyl 
chain spacing, distance, and their packing tightness in the solution, in a way that is either 
energetically favored or disfavored, therefore resulting in different immune stimulating 
capacities. On the other hand, AGP structural flexibility in solution would vary due to 
compound conformational variations caused by different acyl chain length/spacing. The 
different conformation and flexibility would not only affect compound biological 
potency, but also potentially lead to certain specificity of AGP - induced immune 
responses. Because different conformations and steric flexibility would allow or limit 
binding access for certain cell surface receptors and molecules, resulting in increased or 
decreased specificity for certain signaling pathways, therefore triggering only particular 
and beneficial responses. Because AGPs are synthetic chemical compounds, their 
structures can be designed and modified for clinical and medicinal needs. This is a great 
advantage for AGP compound series because the research work focusing on structure, 
potency, and specificity of induced responses could lead to the discovery of novel
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adjuvant candidates as potential clinical products with high efficiency and desired 
specificity, but low toxicity and fewer side effects.
Cytokine combination measured with Luminex 100 Analyzer
The Luminex Analyzer provided an efficient system that allows simultaneous 
measurement of several cytokines in a single sample with a relatively small volume. 
However, one disadvantage of such a system is that only one dilution factor is allowed 
for the single test sample, therefore, it is difficult to keep all cytokine data within each 
proper standard curve range due to significant variations within cytokines released from 
the same sample. The combination of cytokines that we chose for initial studies included 
IL-ip, IL-6, IL-8, IL-10, and TNF-a. IL-8 levels were frequently higher than the highest 
standard curve value, and could not be calculated as accurately as other cytokines with 
the same dilution factor. Therefore, IL-8 is not recommended to be included in this one- 
sample, multiple-cytokine assay of in vitro cell supernatants using the Luminex Analyzer.
Effect of DMSO on cell pretreatment
As described in Materials and Methods, PMA applied in this study for cell pretreatment 
was dissolved in DMSO for storage at -  20 °C. Previous data indicated that DMSO 
could act as a stimulant for certain cell lines. PMA stock was diluted about 400,000-fold 
in culture medium for cell pre-stimulation in this study, therefore, only trace amounts of 
DMSO was actually added to the cells. However, the effect of DMSO on cell 
pretreatment and stimulation was not tested in this study.
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Preference of MonoMac-6 for in vitro cell assay system
Compared to U937 cells, MonoMac-6 cells showed increased adhesion to 
stimulated and unstimulated HUVEC in previous studies, indicating that MonoMac-6 is a 
more mature monocytic cell line (4\  Therefore, compared to the relatively immature U937 
cells, MonoMac-6 cells may serve as a better endotoxin indicator because this cell line 
represents a more advanced and mature stage of myelomonocytic development(3). 
Untreated MonoMac-6 cells have been found to be closely related to human monocytes 
from many aspects, such as expression of NaF-sensitive non-specific esterase, production 
of reactive oxygen, phagocytosis activity, surface expression of CD 14 and many other 
monocyte-specific cell surface molecules, as well as cytokine productions upon 
stimulation (4). MonoMac-6 cells could produce a variety of human cytokines, such as 
IL-1 a/p, IL-6, and TNF-a, after being induced with lectin phytohaemagglutinin A 
(PHA, a known T cell activator). Maximum cytokine levels were found 24 hours after 
stimulation with kinetic studies
Data from our current study is consistent with the previous findings. MonoMac-6 
cells require less time for PMA pre-stimulation compared with U937 cells (3 hours vs. 
overnight) in our study. MonoMac-6 cells also had higher levels of cytokine secretion 
than U937. Therefore, MonoMac-6 cell line is recommended as a better human cell line 
for use in an in vitro cell assay system. If necessary, an in vitro biological assay could be 
completed within a one-day time period using MonoMac-6 cells with a 5-hour cell 
stimulation period. Overnight incubation is preferred for higher cytokine levels. Based on 
the above data, a brief outline of a proposed human in vitro cell assay procedure using 
MonoMac-6 cells is described as follows:
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Materials
1. MonoMac-6 cells (Deutsche Cell Bank, Germany)
2. Cell culture medium and supplements:
RPM I1640 (SIGMA Catalog #5886) with 10% heat inactivated fetal 
bovine serum (HyClone)
L-glutamine 2 mM (SIGMA, catalog #G7513)
Penicillin (10.0 units/ml) & Streptomycin (10.0 pg/ml) 
(Penicillin/Streptomycin, SIGMA catalog #P7539)
Non-essential amino acid solution (L-Alanine, L-Asparagine, L-Aspartic 
acid, L-Glutamic acid, Glycine, L-Proline, and L-Serine. 0.2x. SIGMA 
catalog #M7145)
Oxaloacetate (150 pg/ml), pyruvate (50 pg/ml), and bovine insulin (8.2 
pg/ml), (OPI medium supplement, SIGMA catalog #05003).
3. 4-beta-phorbol-12-myristate 13-acetate (PMA, SIGMA catalog #P-8139), 
stock 10 pg/ml in DMSO and store at -  20 °C.
4. Lipopolysaccharide (LPS, SIGMA catalog #L-3012), stock 100 pg/ml in 
PBS and store at -  20 °C.
5. Fluorokine MAP Human Base Kit (R&D systems, catalog #LU000)
6. Luminex 100 Analyzer (Luminex Corporation)
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Experimental procedures
1. Start fresh cell culture weekly in T75 culture flask with 35 ml culture medium.
2. Incubate cell culture in a 37 0 C CO2 incubator for three days, then feed once 
with 15 ml fresh culture medium, and incubated again overnight.
3. Harvest cells from culture flask, reusupend in fresh medium, count, and 
distribute to 96-well culture plate at 100 pl/well with 2.5 x 1005 cells/well.
4. Dilute PMA to 5 ng/ml in culture medium and added to the cells on the 
culture plate at 100 pl/well (PMA final concentration at 2.5 ng/ml in each 
well).
5. Incubate the plate in a 37 0 C CO2 incubator for three hours.
6. Dilute stimulants in fresh culture medium at 3-fold of desired concentrations 
and add 100 pi to cells.
7. Incubate the plate in a 37 0 C CO2 incubator for 20 - 22 hours. (An incubation 
of 3 hours is optional if a one-day time period assay is preferred.)
8. Spin the plate at 1100 rpm (BECKMAN, Allegra ™ 6R Centrifuge) for 3 
minutes, harvest 200 pi supernatant from each well, and store all supernatant 
samples at -  20 0 C.
9. Thaw samples at room temperature. Quantitate human cytokines, including 
TNF-a, IL-1 p, IL-6, and IL-10, with Fluorokine MAP Human Base Kit and 
Luminex 100 Analyzer.
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CHAPTER 3
Characterization of Specific Involvement of Toll-like Receptor-4 in Signaling 
Pathways for LPS and Synthetic Lipid A Compounds
Introduction
Lipopolysaccharide (LPS, or endotoxin) is the major component of the outer 
membrane of Gram-negative bacteria. LPS can be highly toxic when introduced into the 
bloodstream of an animal, and clinical symptoms may include fever, multi-organ failure, 
septic shock, and even death in some cases (5). A variety of biochemical pathways can be 
activated with LPS stimulation, resulting in the above severe clinical syndromes. Among 
the many complicated mechanisms, one of the most important phenomena is the LPS - 
induced activation of monocytes and other phagocytes, because this is one of the major 
events that under certain circumstances can lead to the serious, complicated, or 
sometimes even life -  threatening consequences, such as septic shock (A\  Therefore, 
signal transduction pathways and cell surface receptors for LPS recognition by 
monocytes and phagocytes have received a great deal of attention in the research field. 
The search for the specific membrane receptors for LPS on these cells has led to the 
discovery of the involvement of Toll -  like receptor 4 (TLR-4) and CD14.
It has been well understood that human Toll-like receptors can recognize, and 
usually function by direct binding with highly conserved microbial molecular features, 
and initiate intracellular signal transduction. Therefore, these receptors are critical 
components of the host innate immune systems. Various immune cells of the innate 
immune system, such as macrophages and dendritic cells (DCs), express Toll-like
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receptors on cell surface. With these surface receptors, the host innate immune system 
can detect microbial infections or vaccine/adjuvant that contains highly conserved 
microbial ligands, and activate antigen-presenting cells (APCs), resulting in 
phagocytosis, up-regulation of major histocompatibility complex (MHC) and cell surface 
co-stimulatory molecules, antigen presentation, as well as the secretion of inflammatory 
cytokine and chemokines. Thus, naive T- and B-lymphocytes of the adaptive immune 
system may be stimulated, and antigen - specific T cell receptors (TCR) and B cell 
receptors (BCR) may be generated by clonal selection and expansion. Meanwhile, 
cytokines and chemokines may further direct the immune responses against the microbes 
by guiding the antigen - specific lymphocyte maturation, leading to an effective, antigen- 
specific adaptive immunity as well as a long - term immunological memory. Such an 
effect is also essential for a successful vaccination. In 1997, the first human homologue 
of Drosophila Toll was discovered and cloned, later designated as “TLR-4”. Since then, a 
great deal of research work has been performed focusing on TLR-4 functions and its 
signaling mechanism. Results of these studies indicated that TLR-4 played a key role in 
signaling of host cells in response to LPS (see Chapter I) and to other bacterial cell 
surface components, such as lipoteichoic acid (LTA) from Gram -  positive bacteria.
CD14, a glycosyl phosphatidylinositol -  anchored protein of 55 kDa is another 
well characterized LPS receptor (8\  CD14 is normally expressed as a membrane -  bound 
cell surface receptor (mCD14) on monocytes and macrophages. On polymorphonuclear 
granulocytes, CD14 was found to be expressed in a 10-fold -  lower amount compared to 
monocytes and macrophages l4). CD14 can also be secreted and expressed in the serum as 
a soluble receptor (sCD14). In patients with acute infections, the concentration of sCD14
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can be three- to four-times -  higher compared to the healthy individuals (4,7’8). Membrane 
- bound CD14 lacks an intracellular domain, therefore, it is unlikely that CD14 could act 
alone to transmit signals directly into the cell. Rather, CD 14 appears to be part of a multi- 
component UPS receptor complex, which is responsible for the initiation and transduction 
of intracellular signaling for LPS, leading to cell activation(8). In the meantime, available 
research data also indicated that CD14 -  negative cells, such as endothelial or epithelial 
cells, were non-responsive to LPS stimulation. However, these cells can be activated by 
LPS with the addition of sCD14. The mechanism behind such a phenomenon is not yet 
completely understood, but with data showing that sCD14 did not simply serve as a 
shuttle for LPS transfer in this case (8, n>.
The current understanding of LPS signaling mechanism indicates that the 
interaction of LPS with CD 14 requires LPS binding protein (LBP). LBP is an acute -  
phase protein that is synthesized by hepatocytes, and is normally expressed as a soluble 
serum protein. LBP can form complexes with LPS through high -  affinity attachment to 
the lipid A moiety, which in turn transfer LPS to mCD14, and catalyzes LPS recognition 
by mCD14. The LPS -  CD14 complexes then initiate the intracellular signaling by 
binding and aggregating cell surface TLR-4 receptors. Another small glycosylated 
protein, MD-2, has also been shown to be part of the TLR-4 signaling complex for its 
optimal function (2,33). It has been known that TLR-4 mediates LPS intracellular signaling 
via different pathways, which lead to the induction of various genes that function in host 
defense. Two major signaling pathways have been identified, including the common 
MyD88 -  dependent pathway and the specific T r if -  dependent pathway (28’ 29\
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LPS signaling via these pathways results in the activation of NF-kB transcription factor 
as well as extracellular signal -  regulated kinase, c-Jun N-terminal kinase, and p38 
mitogen -  activated protein kinase. Therefore, intracellular signaling of LPS activates 
monocytes and macrophages, and mediates the production of inflammatory cytokines 
such as TNF-a, IL-ip, IL-6, and other cytokines (4' 5’28).
In Chapter II of this study, we demonstrated that in vitro stimulation with LPS or 
synthetic lipid A compounds could activate human monocytic cell lines (MonoMac-6 and 
U937) and result in production of cytokines. In order to better characterize the specific 
involvement of TLR-4 in signaling pathways for LPS, and possibly for synthetic lipid A 
compounds as well, human MonoMac-6 cell line was again selected as an experimental 
model in this chapter. Inhibition studies were performed with the previously developed in 
vitro cell assay system, using monoclonal anti-human-TLR-4, clone HTA125, as receptor 
blocker to identify TLR-4 function in macrophage activation when stimulated with LPS 
and other lipid A compounds. HTA125 is a monoclonal antibody that has been used to 
detect or block human TLR-4 in previous studies(8’10, u \  therefore, fluorescence - 
conjugated HTA125 was applied in this project to verify and characterize TLR-4 receptor 
surface expression on human MonoMac-6 cells. Meanwhile, binding studies have been of 
great value in unraveling the interactions of LPS with the cell surface (4,7’8), so in the 
present study, fluorescence - conjugated LPS was used for cell staining in order to 
generate LPS direct-binding curves with MonoMac-6 cells, followed by verifying LPS- 
specific binding to the cell lines by detecting binding inhibition with non-labeled LPS 
and HTA125. The significance of CD 14 and LBP involvement in LPS direct binding to 
cell surface was also investigated during the development of a cell staining procedure. By
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comparing inhibition data generated from biological assay and LPS direct binding assay, 
we further characterized TLR-4 functions in signaling and cell activation pathways for 
LPS and lipid A compounds. In particular, the consistent appearance of high levels of 
fluorescent background during our studies of identifying surface expression of TLR-4, as 
well as evidence of inhibition during co-staining using flow cytometry immunoreagents 
led us to characterize the interaction of HTA125 with the human cell line.
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Materials and Methods
Materials
Antibodies and Immunoreagents
Antibodies were purchased from commercial sources: Phycoerythrin (PE) 
conjugated anti-human TLR4, clone HTA125, IgG2a (eBioscience); Purified functional- 
grade anti-human TLR4, clone HTA125, IgG2a (eBioscience); Fluorescein 
isothiocyanate (FITC) conjugated HTA125 (BIOCARTA); Biotinylated mouse anti­
human TLR4 clone HTA125 (BD Biosciences); FITC mouse anti-human CD 14, clone 
1.BB.211, IgG2a (U.S. Biological); FITC mouse anti-human CD14, clone Tuk 4, IgG2a 
(Cell Sciences); PE mouse anti-human CD14, clone CRIS-6, IgGl (BioSource
International); PE mouse anti-human CD14, cloneMcpP9, IgG2b (BD Biosciences); APC
mouse anti-human CD14, clone M5E2, IgG2a (BD PharMingen); FITC and unlabeled 
mouse anti-human IgG Fc receptor CD16, clone 3G8, IgGl (PharMingen); FITC and 
unlabeled mouse anti-human IgG Fc receptor CD32, clone FL18.26, IgG2b 
(PharMingen); FITC and unlabeled mouse anti-human IgG Fc receptor CD64, clone 10.1, 
IgGl (PharMingen); PE, FITC and unlabeled mouse isotype IgGl, clone MOPC 21 
(PharMingen); mouse IgG2a, clone G155-178 (PharMingen); mouse IgG2b, clone 27-35 
(PharMingen). Purified human immunoglobulin IgGl, IgG2, IgG3, IgG4, and IgG fc 
were purchased from Fitzgerald Industries. Other immunoreagents were obtained 
commercially: PE conjugated NeutrAvidin (Molecular Probes) and FITC streptavidin 
(Pierce); Mouse Ig was obtained from pooled normal mouse serum, and fractionated in 
50% ammonium sulfate followed by serial ultrafiltration in PBS. Rabbit polyclonal anti-
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human TLR4 was purchased from Torrey Pines Biolabs, Inc, and FTTC-goat anti-rabbit 
Ig was purchased from PharMingen. Recombinant soluble human CD 14 and LPS binding 
protein (LBP) were purchased from R&D Systems.
Human MonoMac-6 cell line and culture conditions
MonoMac 6 cells were obtained from Deutsche Cell Bank (Germany), and were 
grown in RPM I1640 (SIGMA) plus 10% heat inactivated fetal bovine serum (HyClone), 
2 mM L-glutamine (SIGMA), 10.0 units/ml Penicillin, 10.0 pg/ml Streptomycin 
(Penicillin/ Streptomycin, SIGMA), 0.2x non-essential amino acid solution (SIGMA), 150 
pg/ml oxaloacetate, 50 pg/ml pyruvate, and 8.2 pg/ml bovine insulin (OPI medium 
supplement, SIGMA).
Cells were grown in the above culture media in T75 culture flasks in a 37 °C CO2  
incubator. The MonoMac-6 cell line is not adherent, therefore after harvesting by 
centrifugation, cells were resuspended in fetal bovine serum with 6% dimethyl 
sulphoxide (DMSO) at 2.0 x 106 cells/ml, and frozen at - 70 °C in 1.0 ml/vial aliquots. 
Stimulants
Phorbol 12-myristate 13-acetate (PMA, Sigma) powder was dissolved in dimethyl 
sulphoxide (DMSO, Sigma) to reach a concentration of 1.0 mg/mL, and stored in aliquots 
at -70°C. Cell pretreatment procedure was described in Chapter 2.
For the purpose of appropriate inhibition test and accurate data comparison, both 
labeled and unlabeled LPS used in this study were from the same E. coli serotype 
(055:B5), and both preparations went through the same purification procedures.
Unlabeled LPS from E. coli serotype 055:B5 was obtained from Sigma, and dissolved in
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PBS and stored frozen in aliquots at a concentration of 10.0 pg/mL. Alexa Fluor 488 
conjugated LPS (E. coli serotype 055:B5) was obtained from Molecular Probes.
MPL™ Adjuvant and AGP compounds used in this study were kindly provided by 
Corixa Corporation (Montana Facility).
Flow Cytometry (FACSCalibur, Becton Dickinson)
Flow cytometry was applied for analysis of fluorescence - conjugated antibody 
staining and labeled LPS direct binding to cells, as well as calculation of mean 
fluorescence intensity (MFI) of each sample with the installed computer software “Cell 
Quest”. LPS direct binding curves were generated for each cell line based on sample MFI 
values (MFI vs. LPS concentrations). For direct binding inhibition, percentage of 
inhibition was calculated based on sample MFI values as well, and inhibition curves were 
generated according to the values of percent inhibition and inhibitor concentrations.
Luminex 100 Analyzer (Luminex Corporation)
A Luminex 100 Analyzer was applied in this study for measurement of human 
cytokines as described in Chapter 2.
Methods
Inhibition study with in vitro human cell assays
Biological inhibition assays were performed based on the previously developed in 
vitro human cell assay using MonoMac-6 cells, as described in Chapter 2. After the 
appropriate cell pre-stimulation with PMA, monoclonal anti-human-TLR-4 (HTA125) 
and other potential inhibitors were diluted in cell culture medium and added to the cells at
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50 pL/well. The antibody isotype control, mouse IgG2a, was also included in the assay as 
a potential inhibitor for comparison with HTA125. Cells in uninhibited-control wells 
received fresh medium only. The pre-stimulated cells were incubated with the inhibitors 
in the 37 °C CO2 incubator for two hours. At the end of the incubation period, stimulants, 
including LPS, MPL™ adjuvant, and AGP compounds (TEOA-RC-527 and TEOA-RC- 
529) were diluted in fresh culture medium and added to the cells at 50 pL/well for cell 
stimulation following the developed cell assay procedure. After proper incubation, 
samples were harvested and cytokine secretion was measured with the Luminex system 
as described previously.
Verification of TLR-4, CD14, and FcyR surface expression on MonoMac-6 cells
For direct staining, cells were cultured, harvested, and pre-stimulated following 
the developed in vitro cell assay procedure. At the end of cell pre-stimulation period, the 
96-well cell culture plate was centrifuged at 1100 rpm for 3 minutes, and the supernatant 
was removed from each well. Cells were washed twice by filling each well with 300 pL 
staining buffer (PBS plus 2.5% fetal bovine serum and 0.025% sodium azide), and 
removing the liquid after centrifugation. After washing, fresh staining buffer was added 
to the plate at 100 pl/well to resuspend the cells. Fluorescence (FITC, PE, or APC) 
conjugated monoclonal antibodies and appropriately labeled mouse isotype controls were 
added to the cells for staining. The plate was incubated at 4 °C in the dark for 30 minutes. 
At the end of the incubation period, fresh staining buffer was added to the plate at 175 
pL/well. The plate was centrifuged at 1100 rpm for 3 minutes, and supernatant was 
removed from each well. Cells were washed again by filling each well with 300 pL 
staining buffer and removing the liquid after centrifugation. After washing, cells were
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resuspended with 200 pL/well of cold (4 °C) 1% paraformaldehyde (PFA), and 
transferred to individual sample acquisition tubes. Another 200 p.L/tube of cold (4 °C)
1% PFA was added to all samples for fixation. Samples were analyzed with a flow 
cytometer (FACSCalibur, Becton Dickinson), and mean fluorescence intensity (MFI) of 
10,000 or 20,000 cells per sample was measured with the installed software “CellQuest”. 
Fluorescent HTA125 direct binding curves were generated based upon MFI values 
obtained from samples stained with HTA125 at different concentrations (MFI values vs. 
fluorescent HTA125 concentrations). Appropriate HTA125 concentrations within the 
linear section of the direct binding curve were identified as inhibitable concentrations, 
which would be applied in further inhibition studies.
For indirect staining, cells were treated as above, incubated with biotinylated 
monoclonal antibody or unlabeled primary antibody, washed, and fluorescence - 
conjugated NeutrAvidin or secondary antibody was added and incubated for 30 minutes. 
Cells were then washed, and resuspended in fixative and treated as above.
Inhibition of HTA125 direct binding to cell surface
Various mouse immunoglobulin isotypes and monoclonal mouse anti-human 
FcyR antibodies were applied to competitively inhibit PE -  HTA125 direct binding to 
MonoMac-6 cells, at a concentration of PE -  ETTA125 that had been found previously to 
lie within the linear section of the PE - HTA125 direct binding curve. Each unlabeled 
inhibiting antibody was diluted in staining buffer and added to the cells simultaneously 
with PE -  HTA125. The uninhibited control samples received PE -  HTA125 only. After 
incubation at 4 °C following the cell staining procedure as previously described, all 
samples were analyzed with a flow cytometer (FACSCalibur, Becton Dickinson) and MFI
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value of each sample was measured with “CellQuest”. Percentage of inhibition was 
calculated using the difference of MFI of uninhibited control samples minus MFI of 
inhibited samples, divided by MFI of uninhibited control samples.
Generation of fluorescence - conjugated LPS direct binding curves
Alexa Fluor 488 conjugated LPS (E. coli serotype 055:B5, Molecular Probes) 
was applied to stain MonoMac-6 cells in order to generate a linear LPS direct-binding 
curve with the cell line. Cells were harvested and pretreated with PMA as previously 
described. At the end of the pretreatment period, the plate was centrifuged at 1100 rpm 
for 3 minutes, and culture supernatant was removed from all wells. Alexa - conjugated 
LPS was diluted in RPM I1640 media (SIGMA) containing 1.0 pg/ml of LPS binding 
protein (R&D Systems) and 1.0 pg/ml of human soluble CD14 (R&D Systems). Diluted 
LPS was then added to the plate at 100 pl/well for cell staining. The highest 
concentration of fluorescent LPS for this binding test was 50 pg/ml. The plate was 
incubated at 37 °C in the dark for 45 minutes, and washed twice with staining buffer 
(PBS l.Ox + 2.5% FBS + 0.025% Azide). Cells in each well were resuspended in 400 pi 
of cold (4 °C) staining buffer, and LPS direct binding was detected with a flow cytometry 
(FACSCalibur, Becton Dickinson). A LPS direct binding curve with MonoMac-6 cells 
was generated based on flow cytometry data (MFI values vs. LPS concentrations). 
Appropriate LPS concentrations within the linear section of the direct binding curve were 
identified as inhibitable concentrations, which would be applied in further inhibition 
studies using unlabeled LPS and anti-human TLR-4 monoclonal antibody as potential 
inhibitors.
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Inhibition of LPS direct binding with unlabeled LPS and anti-human TLR-4
Unlabeled LPS (£. coli serotype 055:B5) and monoclonal anti-human Toll-like 
receptor 4 (clone HTA125) were applied to inhibit Alexa - conjugated LPS direct binding 
to MonoMac-6 cells. After PMA pretreatment and removal of supernatant, unlabeled LPS 
or anti-TLR4 (HTA125) was diluted in culture media and added to the plate at 100 
pl/well for pretreatment. Control samples received fresh culture media only. The plate 
was incubated in the 37 °C CO2 incubator for 2 hours, and supernatant was removed after 
centrifugation. Cells were then stained with Alexa - conjugated LPS at inhibitable 
concentrations identified from previous step, following cell staining procedure as 
previously described. All samples were analyzed with a flow cytometer (FACSCalibur, 
Becton Dickinson) and MFI value of each sample was measured with “CellQuest”. 
Percentage of inhibition was calculated using the difference of MFI of uninhibited control 
samples minus MFI of inhibited samples, divided by MFI of uninhibited control samples. 
Statistics
For inhibition data obtained from cell assays, statistical analysis was performed with a 
one -  tailed unpaired t - test. Sample sizes for each experiment are available in the figure 
legends. Computer software “Cell Quest” for flow cytometry was applied for analysis of 
fluorescence conjugated antibody staining and calculation of mean fluorescence intensity 
(MFI) of each sample. MFI values were also applied to calculate and compare the 
expression levels of each cell surface marker.
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Results
Verification of TLR-4 surface expression
Surface expression of TLR-4 by MonoMac-6 cell line was verified by flow
cytometry. MonoMac-6 cells stained with PE-HTA125 had weak positive binding signals
(30 -40 mean channel fluorescence, or MCF) when compared with mouse IgG2a isotype
background. A representative histogram is shown in Figure 3-1.
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Figure 3-1. Surface expression of TLR-4 receptor by MonoMac-6 cells.
MonoMac-6 cells were stained with PE-HTA125 (2.0 pg/mL). Histogram peaks from left 
to right: unstained cells (3.1 MFI); PE mouse IgG2a isotype background (clone G155- 
178, 19.71 MFI, black filled); PE-HTA125 (37.4 MFI, gray). MFI was measured using a 
FACSCalibur with computer software “Cell Quest”, counting 20,000 cells per sample.
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Cell staining with rabbit polyclonal anti-human TLR-4 followed by FITC-goat- 
anti-rabbit Ig had fluorescence results similar to PE-HTA125 staining (data not shown). 
Fluorescence background obtained from mouse IgG2a isotype was high, as shown in 
Figure 3-1, up to 19.71 MFI, which was significantly higher than unstained cells (3.1 
MFI) or background due to labeled IgGl (3 MFI) or IgG2b (7 MFI) mouse isotype 
antibodies. FITC-HTA125 (BIOCARTA) and PE-HTA125 (BD) from different 
commercial sources were also tested, and similar results were obtained (data not shown). 
Direct binding of PE-HTA125 was nearly linear (R=0.98) up to 5.0 pg/mL, leading to the 
selection of 5.0 pg/mL as the HTA125 concentration to use for further inhibition studies. 
A typical direct binding curve of PE-HTA125 with MonoMac-6 cell line is shown in 
Figure 3-2.
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Figure 3-2. A typical direct binding curve of PE-HTA125 with human MonoMac-6 
cell line.
MonoMac-6 cells were pretreated with PMA at 2.5 ng/mL for 3 hours. After removal of 
PMA supernatant and washing, PE-HTA125 was diluted in staining buffer and added to 
the cells at a concentration range of 20,15,10, 5, 2.5,1.0, and 0.0 pg/mL. MFI values 
were measured using a FACSCalibur with computer software “Cell Quest”, counting 
20,000 cells per sample.
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Utility of HTA125 and mouse IgG2a isotype in biological inhibition assays
Functionality of TLR-4 receptor on MonoMac-6 cells was assessed by an in vitro 
cell assay coupled with receptor blocking antibodies, and cytokines were induced by the 
TLR-4 agonist LPS, as well as other lipid A compounds. Using concentrations of the 
stimulants in the middle section of the dose-response curves previously generated in 
Chapter 2, stimulants were co-cultured with HTA125 to determine if this antibody could 
inhibit TLR-4 -  based cytokine induction. Data indicated that HTA125 was a successful 
inhibitor for LPS as well as for other synthetic lipid A stimulants (Figure 3-3). Using 
MonoMac-6 cells, cytokine induction by 0.5 ng/mL LPS was inhibited from 24% to 86% 
by HTA125, depending upon the types of cytokine and HTA125 concentrations. In the 
same experiments using the same concentrations as HTA125, mouse IgG2a, an isotype 
control matched to HTA125, inhibited LPS (0.5 ng/mL)-induced IL-10 production up to 
18%, but not LPS (0.5 ng/mL) -  induced IL-1J3 and IL-6. Curiously, IgG2a isotype 
enhanced the production of TNF-a up to 21%. Similar inhibition results were obtained 
when other stimulants were tested, including MPL adjuvant and two synthetic lipid A 
compounds (AGPs) with different biological potency: TEOA-RC-527 (the most potent 
compound) and TEOA-RC-529 (the least potent compound). As shown in Figure 3-3, the 
significant reduction of cytokine secretion by co-incubation with HTA125 strongly 
suggested that TLR-4 receptor played a critical role in LPS, MPL and AGP signaling 
pathways.
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Figure 3-3. Histograms illustrating percentage of inhibition generated by HTA125 and mouse 
IgG2a isotype from MonoMac-6  cells stimulated with LPS, MPL adjuvant, and AGP compounds 
RC-527 and RC-529. MonoMac-6  cells were pretreated with PMA at 2.5 ng/mL for 3 hours, then 
stimulated with LPS (0.5 ng/mL), MPL (5.0 pg/mL), AGP compound TEOA-RC-527 (0.5 
pg/mL) or TEOA-RC-529 (5.0 pg/mL) for 5 hours. In addition, each stimulant was co-incubated 
in the presence of monoclonal antibody HTA125 which has specificity for human TLR-4 
receptor, or mouse IgG2a which is the antibody isotype control for HTA125. Top panel: 
percentage of inhibition measured with TNF-a secretion; Bottom panel: percentage of inhibition 
measured with IL-6  secretion. Data are shown as means + STDEV, n = 5. Statistical analysis was 
performed with one -  tailed unpaired t -  test. Percentage of inhibition generated by HTA125 
(solid bars) showed significant difference (p < 0.05) over control values generated by mouse 
IgG2a isotype control (empty bars).
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Direct binding of fluorescence - conjugated LPS with MonoMac-6 cells
Direct binding of fluorescent LPS to MonoMac-6 cell line was tested. A typical 
histogram analysis of Alexa Fluor 488 LPS binding peaks is shown in Figure 3-4. Linear 
binding curve was obtained from this test with Alexa-LPS staining (Figure 3-5), 
calculated based upon flow cytometry data (MFI values vs. LPS concentrations). 
According to the linear binding curve, a concentration of Alexa-LPS at 5.0 pg/mL was 
selected as inhibitable concentration for LPS direct binding, and was applied for further 
inhibition studies.
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Figure 3-4. Direct binding of Alexa Fluor 488 conjugated LPS with MonoMac-6
cells.
MonoMac-6 cells were pretreated with PMA for 3 hours. After removal of supernatant, 
Alexa - LPS was diluted in RPM I1640 with 1.0 ug/mL LBP and 1.0 pg/mL soluble 
CD 14 for cell staining at 3 7 0 C in the dark for 45 minutes. Alexa-LPS concentration 
(from left to right): 0 (Black filled), 1,5,10, and 20 pg/ml (heavy gray).
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Figure 3-5. Line graph illustrating typical direct binding curve of Alexa Fluor 488 
conjugated LPS with human MonoMac-6 cell line. Cells were pretreated with PMA at 2.5 
ng/ml for 3 hours. After removal of supernatant and washing, Alexa - LPS was diluted in 
RPMI1640 media (SIGMA) containing 1 pg/ml LBP and 1 pg/ml soluble human CD14, 
and added to the cells. Alexa-LPS concentrations for cell staining: 50,40, 30, 20,10,5, 
1.0, 0.5, 0.0 pg/ml (Based upon whole molecule weight). MFI values were measured 
using a FACSCalibur with computer software “Cell Quest”, counting 20,000 cells per 
sample.
Inhibition of LPS direct binding with unlabeled LPS and anti-human TLR-4
In order to verify LPS-specific binding to human MonoMac-6 cells, unlabeled 
LPS from the same E. coli serotype (055:B5) as Alexa-LPS was co-incubated with 
Alexa-LPS (5.0 pg/ml). Percentage of inhibition was calculated using mean fluorescence 
intensity units, compared to uninhibited control samples. Using MonoMac-6 cells, an 
average of 56% inhibition was achieved by a 10-fold concentration of unlabeled LPS (50 
pg/ml) pre-incubation, and an average of 38.5% inhibition was obtained by pre­
incubation of a 5-fold concentration (25 pg/ml) of unlabeled LPS. The time period for 
unlabeled LPS pretreatment was 1 hour, and Alexa-LPS was directly added to the cells 
without removing the unlabeled LPS pretreatment.
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A competitive inhibition of LPS direct binding to the cell surface by anti-human 
TLR-4 antibody (clone HTA125) pretreatment was also investigated. However, the 
percentage of inhibition obtained from this procedure was lower compared to the 
previous experiments using unlabeled LPS as the inhibitor (Figure 3-6). Using 
MonoMac-6 cells, an average of 18% and 22% inhibition was achieved by monoclonal 
anti-TLR4 pretreatment at 50.0 and 70.0 pg/ml, respectively, followed by Alexa-LPS 
staining at 5.0 pg/mL.
LPS 50 ug/mL HTA125 50 ug/mL
Figure 3-6. Histograms illustrating percentage of inhibition generated by unlabeled LPS or 
HTA125 from MonoMac-6 cells stained with Alexa Fluor 488 conjugated LPS. Cells were 
pretreated with PMA at 2.5 ng/ml for 3 hours. After removal of supernatant and washing, Alexa - 
LPS was diluted in RPMI1640 media (SIGMA) containing 1 pg/ml LBP and 1 pg/ml soluble 
human CD14, and added to the cells for cell staining with the presence of unlabeled LPS (50 
pg/mL) or HTA125 (50 pg/mL). Uninhibited control samples received Alexa -  LPS only. MFI 
values were measured using a FACSCalibur with computer software “Cell Quest”, counting 
20,000 cells per sample. Percentage of inhibition was calculated using the difference of MFI of 
uninhibited control samples minus MFI of inhibited samples, divided by MFI of uninhibited 
control samples. Data are shown as means ± range, n = 4. Statistical analysis was performed with 
one -  tailed unpaired t -  test. (*)= statistical difference at p<  0.05. Percentage of inhibition 
generated by unlabeled LPS (filled bar) showed significant difference (p < 0.05) over percentage 
of inhibition generated by unlabeled HTA125 (empty bar).
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General inhibition of mouse IgG2a isotype antibodies by mouse immunoglobulin
Because labeled mouse IgG2a isotype antibodies appeared to possess high 
background binding to MonoMac-6 cells, we first sought to verify that epitopes of mouse 
Ig immunoglobulin molecules were involved in this background phenomenom, rather 
than nonspecific interactions of cells with fluorescent molecules of labeled antibodies. 
Therefore, MonoMac-6 cells were incubated simultaneously with FITC mouse IgG2a and 
unlabeled mouse Ig (0.5 mg/mL or 1 mg/mL) which resulted in ablation of the FITC 
signal. In a similar experiment, labeled anti-CD14 that possessed the mouse IgG2a 
isotype was blocked by mouse Ig. Low background fluorescence due to FITC mouse 
IgGl (2.4 MFI) and FITC mouse IgG2b (2.8 MFI) was not affected by addition of mouse 
Ig, nor was the fluorescent signal of FITC anti-CD14 of IgGl isotype (91.5 MFI) affected 
by simultaneous addition of mouse Ig (93.4 MFI). However, MFI of APC-IgG2a (33.2 
MFI) was lessened by addition of mouse Ig to 10.4 MFI. Further investigations also 
found that labeled HTA125 (mouse IgG2a) could be blocked by mouse Ig. In this respect, 
co-incubation with mouse Ig significantly decreased MFI of PE-HTA125 as well, from 
30.3 MFI to 3.9 MFI.
To verify that IgG2a epitopes were shared by HTA125 and mouse IgG2a, 
unlabeled HTA125 was added to MonoMac-6 cells together with PE-IgG2a (clone G155- 
178). PE IgG2a fluorescence (MFI 15.3) was inhibited 63%, 62%, and 57% by 50, 20 and 
10 ug/mL HTA125, respectively.
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Characterization of inhibition of HTA125
Direct binding of PE-HTA125 was lessened competitively by a number of 
different inhibiting antibodies, including various mouse immunoglobulin isotypes and 
mouse anti-human IgG Fc receptor CD16, CD32, and CD64. Each potential inhibitor was 
diluted in staining buffer to 50, 20,10, 5, and 1 pg/mL, and added to Mono Mac-6 cells 
simultaneously with PE-HTA125 in order to achieve an inhibition curve. Unlabeled 
mouse immunoglobulin of IgGl, IgG2a, or IgG2b isotypes was incubated simultaneously 
with PE-HTA125, and relative inhibition was calculated. IgG2a isotype (clone G155- 
178) had the highest inhibition (up to 93%) of HTA125 binding. Mouse IgGl (clone 
MOPC-21) and IgG2b (clone 27-35) isotypes had no significant effects on HTA125 
binding. Mouse IgG2a was about 17-fold more inhibitory than IgGl or IgG2b, based 
upon relative inhibition at 5 pg/mL. Figure 3-7 shows typical data obtained from this 
inhibition study.
To determine if a specific FcyR might be involved in this phenomenon, mouse 
monoclonal antibodies with specificity for anti-human IgG Fc receptors CD16 (FcRylll), 
CD32 (FcRyll), or CD64 (FcRyl) were incubated simultaneously with FITC-HTA125. 
Maximal inhibition by anti-CD64 (clone 10.1, isotype IgGl) was 50%, and maximal 
inhibition by anti-CD32 (clone FLI8.26, isotype IgG2b) was 20% - 25%. Anti-CD16 
(clone 3G8, isotype mouse IgGl) had no significant inhibition effect on HTA125 direct 
binding (Figure 3-7). Based upon relative inhibition (5 pg/mL concentrations), anti-CD64 
was almost 3-fold more competitive for HTA125 than anti-CD32.
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Figure 3-7. Line graph illustrating inhibition of HTA125 direct binding to MonoMac-6 
cells by mouse isotypes and monoclonal mouse anti-human IgG FcR. Unlabeled mouse 
immunoglobulin isotypes and mouse anti-human IgG Fc receptor CD16, CD32, and 
CD64 were each diluted in staining buffer to 50 ,20 ,10 ,5 ,1 , and 0.0 pg/mL, and added 
to the cells simultaneously with PE conjugated HTA125. Uninhibited control samples 
received PE -  HTA125 only. Mean fluorescence intensity (MFI) was measured on a 
FACSCalibur using computer software “Cell Quest”, counting 20,000 cells per sample. 
Percentage of inhibition was calculated using the difference of MFI of uninhibited control 
samples minus MFI of inhibited samples, divided by MFI of uninhibited control samples. 
Mouse IgGl clone MOPC-21 (empty squares); Mouse IgG2a clone G155-178 (empty 
triangles); Mouse IgG2b clone 27-35 (empty circles); Mouse IgGl anti-CD16, clone 3G8 
(filled circles); Mouse IgG2b anti-CD32, clone FLI8.26 (filled squares); Mouse IgGl 
anti-CD64, clone 10.1 (filled triangles). Data are shown as percentage of inhibition vs. 
inhibitor concentrations (pg/mL) from one representative experiment of 3 reproducible 
experiments.
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Presence of human IgG Fc receptors upon MonoMac-6 cells
Using FITC -  conjugated monoclonal mouse anti-human IgG Fc receptors 
(FcyR), including CD 16, CD32, and CD64, MonoMac-6 cells were stained and assessed 
for FcyR density after culture with or without PMA-induced differentiation. All samples 
were analyzed with a flow cytometer (FACSCalibur), and MFI values for each marker 
were calculated with “Cell Quest” software. Flow cytometry analysis found no positive 
binding signals with FITC anti-CD 16 straining, when compared with its antibody iso type 
background. When stained with FITC anti-CD32 or FITC anti-CD64, MonoMac-6 cells 
showed positive binding signals with both antibodies, and the density of CD32 was 
higher than CD64 (Figure 3-8). MFI values for each marker are reported in Table 3 - 1 ,  
which indicates that PMA pretreatment increased surface expression of both CD32 and 
CD64, but the pretreatment effect on such increase was not significant. MFI values of PE 
- TLR-4 staining are also included in Table 3-1, which shows that PMA pretreatment 
increased surface TLR-4 expression as well, even though the percentage of increase was 
not significant.
Table 3-1. Surface expression (MFI values) of CD16, CD32, CD64, and TLR-4 upon MonoMac- 
6 cells. Cells were stained with FITC anti-CD64 (clone 10.1), FITC anti-CD32 (clone FL18.26), 
FITC anti-CD16 (clone 3G8), or PE anti-TLR-4 (clone HTA125). MFI values were measured on 
a FACSCalibur using computer software “Cell Quest”, counting 20,000 cells per sample. 
Percentage of increase was calculated using the MFI difference between the PMA pretreated 
samples and the untreated samples, divided by MFI of the untreated samples. Data are from one 
representative experiment of 5 reproducible experiments.
Fluorescence
conjugated
antibodies
MFI without 
PMA-induced 
differentiation
MFI with PMA- 
induced 
differentiation
Percentage of 
increase
FITC anti-CD 16 3.6 3.6 0.0%
FITC anti-CD32 30.4 31.4 3.0%
FITC anti-CD64 9.9 10.5 6.0%
PE anti-TLR-4 40.5 42.2 4.0%
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Figure 3-8. FACS analysis of CD16, CD32, and CD64 surface expression on MonoMac-6 cells.
Frequency histograms illustrating FITC intensity for MonoMac-6 cells stained with FITC conjugated 
monoclonal mouse anti-human IgG Fc receptors. Top panel: cells stained with FITC anti-CD16 (clone 
3G8, gray line) or FITC -  conjugated mouse IgG l isotype control (clone MOPC-21, black filled). Middle 
panel: cells stained with FITC anti-CD32 (clone FL18.26, gray line) or FITC -  conjugated mouse IgG2b 
isotype control (clone 27-35, black filled). Bottom panel: cells stained with FITC anti-CD64 (clone 10.1, 
gray line) or FITC -  conjugated mouse IgG l isotype control (clone MOPC-21, black filled).
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Because anti-CD64 was capable of inhibiting HTA125, and CD64 was expressed 
upon MonoMac-6 cells (Figure 3-8, bottom panel), we determined if a reciprocal 
relationship would exist such that HTA125 could inhibit anti-CD64 direct binding to the 
cell surface. The effect of HTA125 on anti-CD32 direct binding was also tested for 
reference. Unlabeled HTA125 was simultaneously incubated with FITC - conjugated 
anti-CD64 or FTTC - conjugated anti-CD32, resulting in a slight increase in CD64 MFI 
values, but a slight decrease in CD32 MFI values (Table 3-2).
Table 3-2. Effect of HTA125 on surface expression levels of CD64 and CD32 upon 
MonoMac-6 cells. Cells were stained with FITC anti-CD64 (clone 10.1) or FITC anti- 
CD32 (clone FL18.26) with or without the presence of unlabeled HTA125 at 50.0 or 10.0 
ug/mL. MFI values were measured on a FACSCalibur using “Cell Quest” software, 
counting 20,000 cells per sample. Percentage of gain or loss was calculated using the 
MFI difference between the HTA125 treated samples and the untreated samples, divided 
by MFI of the untreated samples. Data are from one representative experiment of 3 
reproducible experiments.
FITC -  
conjugated 
antibodies
No HTA125 HTA125 50 pg/inL HTA125 10 pg/mL
MFI value MFI value % of gain (+) 
or loss (-)
MFI value % of gain (+) 
or loss (-)
Anti-CD64 8.4 10.2 + 21.4% 10.4 + 23.8%
Anti-CD32 26.1 23.8 -9% 24.2 - 7.3%
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Inhibition of HTA125 by human immunoglobulin isotypes
The effects of human immunoglobulins on HTA125 binding to MonoMac-6 cells 
were investigated and shown in Figure 3-8. Human IgGl, IgG2, IgG3, IgG4, and IgG fc 
were diluted in fresh staining buffer to 50,10, 2.0, 0.4, and 0.0 pg/mL, and added to the 
cells together with biotinylated HTA125 at 1.2 ug/mL. Cells were subsequently stained 
with PE-NeutrAvidin at 5.0 pg/mL. Maximal inhibition for each human immunoglobulin 
was 91% for human IgG fc and human IgGl, 83% for IgG4,28% for IgG3 and only 3% 
for IgG2. Human IgG fc provided about 90% inhibition at all concentrations tested, 
whereas low concentrations of IgG3 did not inhibit HTA125. No concentration of human 
IgG2 had any inhibitory effect upon HTA125 binding. Relative inhibition was calculated 
using 2 pg/mL for each human immunoglobulin isotype. Human IgG Fc was 90-fold more 
competitive than human IgG2 and IgG3, whereas human IgGl and IgG4 were about 75- 
fold and 35-fold more competitive, respectively.
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Figure 3-9. Line graph illustrating inhibition of HTA125 direct binding to MonoMac-6 
cells by human immunoglobulin. Human IgGl (filled circles), IgG2 (filled squares), IgG3 
(filled triangles), IgG4 (empty squares), and IgG fc (empty triangles) were diluted in fresh 
staining buffer to 50, 10, 2.0,0.4, and 0.0 pg/mL, and added to MonoMac-6 cells 
together with biotinylated HTA125 at 1.2 pg/mL. Cells were stained with PE conjugated 
NeutrAvidin at 5.0 pg/mL. MFI of each sample was measured with a FACSCalibur using 
computer software “Cell Quest”, counting 20,000 cells per sample. Percentage of 
inhibition was calculated using the difference of MFI of uninhibited control samples 
minus MFI of inhibited samples, divided by MFI of uninhibited control samples. Data are 
shown as percentage of inhibition vs. inhibitor concentrations (pg/mL) from one 
representative experiment of 3 reproducible experiments.
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Regulation of TLR-4 expression by LPS pretreatment
In order to determine the effect of LPS pretreatment on TLR-4 surface expression, 
MonoMac-6 cells were pretreated with LPS for 24 hours. Data showed that PE-HTA125 
fluoresence signal (MFI) was lessened only 18% by prior 24-hour stimulation with LPS 
from £. coli 055:B5 (10 ng/mL). When the experiment was repeated, TLR-4 surface 
expression was lessened 28% by 50 ng/mL LPS, and 17% by 10 ng/mL LPS. In separate 
experiments, PE-HTA125 signal was decreased 23% and 29% after a 24 hour exposure to 
10 ng/mL LPS. In addition, TLR-4 expression upon MonoMac-6 cells was lessened a 
maximum of 7% if PMA pretreatment was not used. Therefore, TLR-4 expression was 
lessened slightly but consistently by 24 hour exposure to the TLR-4 ligand LPS.
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CD14 surface expression upon MonoMac-6 cells
CD 14 expression was utilized as a positive control for these investigations and 
results are reported here in order to verify, by comparison, the relatively weak 
fluorescence obtained using HTA125 to detect TLR-4. Monoclonal anti-CD14 antibodies 
with various clone numbers and mouse isotypes were utilized. FITC - conjugated anti­
human CD14 clone Tuk 4 (2.5 pg/mL, murine IgG2a, 18 MFI) had greater fluorescence 
than IgG2a isotype control (clone G155-178,12.6 MFI) and unstained cells (3.0 MFI). 
PE-anti-human CD14 (clone CRIS-6,1.5 pg/mL) with a mouse IgGl isotype was much 
brighter (142 MFI) compared to IgGl isotype stainined (2.8 MFI) or unstained cells (2.6 
MFI). PE-anti-human CD14 (clone Mq>P9,2.25 pg/mL) with a mouse IgG2b isotype was 
very bright also (192 MFI) compared to IgG2b-stained (11 MFI) or unstained (3.1 MFI) 
cells. A typical histogram illustrating CD14 surface expression on MonoMac-6 cells was 
shown in Figure 3-10.
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Figure 3-10. FACS analysis of CD14 surface expression on MonoMac-6 cells.
Frequency histogram illustrating PE intensity for MonoMac-6 cells stained with PE -  conjugated 
mouse anti-human CD14 (clone CRIS-6, black line) or MonoMac-6 cells stained with PE -  
conjugated mouse IgGl isotype control (clone MOPC-21, black filled).
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Discussion
In order to study human TLR-4 receptor, we used predominantly the human 
monocytic cell line MonoMac-6. MonoMac-6 cell line was derived from a human 
monoblastoma (53,54,62) and is capable of producing IL -la, IL-lp, IL-6, TNF-a (57) and 
IL-8 f63,64} following LPS stimulation. MonoMac-6 has been consistently more sensitive 
to LPS than U937(56), for which we found similar results (See Chapter II). MonoMac-6 
cell line has also been shown to express CD 1 4 (65). Other studies also indicated that 
pretreatment with calcitriol for two days could significantly enhance MonoMac-6 cell 
surface expression of CD 14, and TNF induced a moderate increase of CD 14 surface 
expression as well -8). Previous binding studies with flow cytometry analysis detected 
direct binding of labeled rough or smooth LPS with MonoMac-6 cells (5-1. For LPS 
concentrations lower than 100 ng/ml, this direct binding process required the presence of 
both CD14 and LPS-binding protein (LBP). For LPS concentrations higher than 100 
ng/mL, binding appeared to be partially CD 14 - dependent, but LBP was no longer 
required for this process(9). Further inhibition studies indicated that the CD14-dependent 
direct binding of labeled LPS to MonoMac-6 cells could be inhibited by a 1000-fold 
excess of unlabeled LPS ('4\
Similar results were obtained from our current study, and we further investigated 
the TLR-4 signaling mechanism by comparing inhibition data obtained from in vitro 
biological assays and LPS direct binding assays. By using monoclonal anti-human-TLR4, 
our data clearly indicated that LPS, as well as synthetic lipid A compounds (MPL and 
AGPs), were signaling through TLR-4 receptor. With antibody (HTA125) blocking,
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TLR4-based cytokine induction was significantly reduced from MonoMac-6 cells, up to 
an 86% decrease in TNF-oc with LPS stimulation (0.5 ng/mL), and up to a 92% decrease 
in IL-6 with AGP compound RC-527 stimulation (50 ng/mL) (Figure 3-3). Compared to 
HTA125, the antibody isotype control, mouse IgG2a had no significant inhibition effects 
toward LPS and lipid A compound stimulation.
However, inhibition data from LPS direct binding assays were more curious. 
Previous studies <-4, ̂  indicated that there were a few critical differences between LPS 
direct binding assay and normal antibody staining assay. In order to obtain ideal binding 
signals, LPS binding assays had to be performed at 37 °C instead of 4 °C, and cell culture 
basal media, such as RPM I1640, had to be applied instead of using a PBS - based 
staining buffer in order to mimic a physiological condition for LPS binding. Moreover, 
LPS direct binding to cells appeared to be partially or completely dependent on the 
presence of LPS-binding protein (LBP) and soluble CD14 in the staining m edia(4’8). 
Based on the available information, with LBP and CD 14 added to the basal media, we 
successfully generated LPS direct binding curves with human MonoMac-6 cell line using 
Alexa-conjugated LPS, and LPS binding was nearly linear up to 40 pg/mL as shown in 
Figure 3-2.
In order to verify specific-LPS binding to cells versus non-specific fluorescence 
staining, unlabeled LPS from the same E. coli serotype as the labeled-LPS was applied to 
inhibit Alexa-LPS direct binding, and the ideal inhibition data indicated LPS specific 
binding to the cells. With only a 10-fold excess of unlabeled LPS (not a 1000-fold 
concentration as reported previously), Alexa-LPS direct binding to MonoMac-6 was 
inhibited up to 56% (Figure 3-6). Furthermore, unlabeled anti-human TLR-4 monoclonal
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antibody (HTA125) was used to inhibit Alexa-LPS direct binding in order to verify LPS 
specific binding to TLR-4 receptor versus non-specific cell surface binding. However, 
data from this inhibition study was less successful. HTA125, up to 70 ug/mL, inhibited 
Alexa-LPS (5.0 pg/mL) direct binding to MonoMac-6 cells by only 22% (Figure 3-6).
The different inhibition data obtained from using unlabeled LPS and unlabeled 
HTA125 indicate a two-step binding mechanism of LPS to TLR-4 receptor for triggering 
signal transduction pathways. This is very similar to that reviewed by Medzhitov in 2001 
(2), proposing that signaling by LPS through TLR-4 occurs after transfer of LPS by 
lipopolysaccharide binding protein (LBP) to CD 14 with subsequent engagement of a 
receptor complex composed of TLR-4, CD 14 and MD-2, and aggregation of human 
TLR-4 on the cell surface by the receptor complex can initiate signaling(61). Our 
inhibition data confirmed that unlabeled LPS could competitively inhibit the primary 
binding step: Alexa-LPS direct binding with LBP and CD14, maybe MD-2 as well, on 
cell surface to form a multi-unit complex. This effective inhibition reduced the signal of 
Alexa-LPS detected on cell surface. Since the transfer and binding of LPS-multi-unit 
complex to TLR-4 receptor, the secondary LPS binding step, is required for signaling, 
therefore HTA125 could effectively inhibit LPS signaling by blocking TLR-4 receptor, as 
indicated by our in vitro inhibition assay data. However, this antibody can only block the 
TLR-4 receptor that is required for the LPS secondary binding step, but it’s not effective 
to inhibit LPS binding to LBP, CD14 and MD-2 to form the multi-unit complex on cell 
surface. Therefore, compared to unlabeled LPS, unlabeled HTA125 is less effective for 
inhibiting LPS direct binding to the cell surface because it only inhibits the LPS
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secondary binding step but not the primary step, while this antibody is still an efficient 
TLR-4 blocker that can inhibit LPS signaling through the receptor.
Because TLR-4 has been well identified as the major signaling receptor for LPS, 
it has been suggested that TLR-4 is involved in LPS uptake and clearance as well. 
However, a recent study conducted at Immunology Department of Scripps Research 
Institute (Tobias, et al. 2004) found no involvement of TLR-4 in cellular LPS uptake 
mechanisms. According to their experiments using monocytes or endothelial cells, no 
difference in LPS uptake and intracellular LPS distribution was observed between TLR-4 
and wild-type cells. After investigating the role of CD 14 and SR-A in LPS clearance 
and detoxification mechanisms, this study concluded that instead of TLR-4, LPS uptake 
in CD14-positive monocytes was predominantly mediated through a CD14 -  dependent 
pathway. In CD14-negative endothelial cells, on the other hand, SR-A was found to play 
a critical role in LPS clearance and detoxification<33).
Indeed, LPS has been well identified as a ligand for binding to scavenger 
receptors(11,13), and our inhibition data obtained from this study was in agreement with 
this finding, suggesting that besides TLR-4, other cell surface receptors might also be 
involved in LPS direct binding as a ligand, but not necessarily in LPS signaling.
HTA125, with specificity for human TLR-4, was unable to block LPS direct binding to 
other surface receptors, which included scavenger receptors. However, unlabeled LPS 
could competitively inhibit labeled LPS direct binding to all types of cell surface 
receptors. Therefore compared to HTA125, unlabeled LPS appeared to be a more 
effective inhibitor for blocking Alexa-LPS binding to cell surface. It is also possible that 
our inhibition data could be extended into support for the above findings obtained at
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Scripps Research Institute. The primary binding step of LPS with CD14, MD-2, and LBP 
forms the multi-unit complex, and there might be double functions and outcomes for this 
complex formation. The transfer and binding of this complex to TLR-4 would initiate 
LPS signaling, or, this complex itself could trigger CD14-mediated pathways for LPS 
uptake, internalization and intracellular transport, leading to LPS clearance and 
detoxification. Certainly, further investigations are required before this can be proposed.
MonoMac-6 cells express other surface molecules characteristic of monocytes. 
MonoMac-6 cells have been found to express FcyRI (CD64) and FcyRII (CD32)(68’69), 
which is in agreement with our data. In addition, U937 cells expressed FcyRI (CD64) and 
FcyRII (CD32) <'10\  We found a low density of CD64, but a higher density of CD32 upon 
MonoMac-6 cells (Figure 3-8). Human monocytic cells THP-1(71) have been found to 
phagocytose using CD64 and CD32, with CD32 phagocytosis occurring predominantly 
with human IgG3 or IgGl isotypes depending upon CD32 polymorphism(72). In general, 
human FcyRI (CD64) and FcyRII (CD32) prefer human IgGl and IgG3 isotypes as 
reviewed by de Hass(73). FcyRI (reviewed by Ravetch and Kinet, 1991)(74) was proposed 
to be the human equivalent of mouse FcR that bound mouse IgG2a(75). For example, 
CD64 can bind ricin-labeled monomeric antibody(76). FcyRI (CD64) in mice, prefers 
mouse IgG2a and is inhibited by IgG (77). Expression of FcyRI (CD64) by MonoMac-6 
and U937 cells was increased by IFN-y but not TNF-a or IL-6, although expression of 
FcyRII (CD32) was unchanged or decreased by these cytokines <69).
In our experiments, PMA was required to increase the receptivity of MonoMac-6 
cells and U937 cells to LPS (See Chapter 2). PMA can induce MonoMac-6 
differentiation (78,79) toward a macrophage phenotype including increased cytokine
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secretion (53). The effect of PMA upon FcR/TLR-4 co-engagement in MonoMac6 cells is 
not significant in our hands, because PMA pretreatment altered CD16, CD32, and CD64 
expression by only 3 -  6% based upon MFI values.
Development of monoclonal antibody HTA125 was reported by Shimazu et a l (38). 
Other monoclonal antibodies with specificity for human TLR-4 have been reported, 
including clone HTA1216 <80) and clone FI-80 (81), which has been identified also as a 
polyclonal antibody(82). Polyclonal anti-human TLR-4 extracellular peptide has been 
used (83). HTA125 was utilized as an inhibitor of cytokine induction by TLR-4 agonists in 
THP-1 cells (39,41,51), human PBMC or monocytes(40,42,48’49,50), transfected 
CHO cells(43), oral epithelial cells(47), HUVEC (84), human liver stellate cells(52) and 
gingival fibroblasts(44). HTA125 has been used also for flow cytometry to detect cell 
surface TLR-4 expression(45,46). We found that HTA125, a mouse monoclonal antibody 
with IgG2a isotype, engages TLR-4 as well as FcR on MonoMac6 cells. Binding of 
mouse IgG2a to U937 cells has been described (75), which was inhibited by human IgG. 
We also found that human IgGl would inhibit HTA125 binding to MonoMac6 cells, 
which is similar to reported human IgGl inhibition of mouse IgG2a binding to U937 cells 
(85). In our hands, human IgG3 did not inhibit HTA125 as well as human IgG4, although 
others using U937 cells found that IgG3 was a strong inhibitor of mouse IgG2a (85). The 
pattern of inhibition of HTA125 by mouse and human antibodies suggests that HTA125 
may exhibit Fc docking upon CD64 -86l
It is possible that our isotype inhibition data and anti-FcyR inhibition data can be 
extended into support for a cross-reactivity between TLR-4 and CD64, as defined by an 
epitope recognized by HTA125. Further studies are warranted before this can be
104
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
proposed. It is more likely that the HTA125 Fc region, which possesses an IgG2a isotype, 
engages CD64 when CD64 is in close proximity to TLR-4 in concurrence with active site 
engagement of TLR-4. This phenomenon is very similar to that described by Kurlander 
(91) who used U937 cells to elucidate a “3-component complex of antibody bound by its 
Fab portion to antigen and by its Fc fragment to an Fc receptor”.
In conclusion, with biological inhibition assays using monoclonal anti-human 
TLR-4 (HTA125), we demonstrated that both MPL and synthetic Lipid A compounds 
(AGPs) were signaling through TLR-4 receptor, similar to their parent molecule LPS. 
Meanwhile, with direct binding assays and binding inhibition studies, we have shown a 
two-step binding mechanism of LPS to TLR-4 receptor, which might first involve a 
complex formation of LPS/LBP/CD14/MD-2, then initiate signal transduction by 
complex binding to and aggregating cell surface TLR-4. Furthermore, our inhibition data 
suggested that besides TLR-4, other receptors might be involved in LPS direct binding to 
the cell surface. A possible cross-reactivity between TLR-4 and CD64 as defined by an 
epitope recognized by monoclonal antibody HTA125 was also investigated. The findings 
from the present study would be helpful for a more comprehensive understanding 
regarding the mechanism of TLR-4 -  mediated recognition of bacterial LPS and synthetic 
Lipid A compounds, which in turn activates innate immune responses. Such information 
could lead to development of novel TLR-4 agonists and antagonists, as candidates for 
potential new clinical products, which function through pharmacological manipulation of 
innate immune responses via pattern recognition receptors.
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CHAPTER 4
The role of scavenger receptor and Toll-like receptor 4 in murine APC activation by 
bioactive particulates and lipopolysaccharide
Introduction
It is well known that silica possesses adjuvant effects(35), and silica exposure has 
been related to the increase of polyclonal antibody synthesis, especially IgA and IgG (50). 
Such activity has also been suggested to be involved in the prevalence of autoimmune 
diseases in patients with silicosis. Research focusing on the pathogenicity of silica 
exposure has provided some explanations regarding the pathogenic mechanism for 
fibrosis and auto-immune disease based on certain recent findings, including the 
understanding of silica -  induced T cell activation that bias a Thl response (18,35). A 
recent study (22) tested the hypothesis that silica and urban particulate matter PM1648 
(Standard Reference Material 1648) could activate antigen presenting cells (APCs), 
resulting in an up-regulation of human immune response as measured by T cell cytokine 
production. Their results showed that silica could up-regulated both Thl and Th2 
lymphocyte-derived cytokine production. On the other hand, PM1648 exposure mainly 
triggered a Th2 response.
Lipopolysaccharide (LPS), the highly conserved component of the outer 
membrane of Gram-negative bacteria, is another exogenous immunomodulator that 
possesses adjuvant effect. LPS exposure triggers host innate immune responses, leading 
to the activation and differentiation of T cells, more towards Thl effector cells (2’31). It 
has been known that LPS can bind to several receptors on macrophages, including toll -
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like receptor 4 (TLR-4), CD14, and Class A scavenger receptor (SR-A), which in turn 
stimulate macrophages to release various inflammatory mediators.
It has been known that inhalation of particulate matter (PM) may influence the 
respiratory health of both children and adults. However, the potential involvement of LPS 
contamination on particulate surface in the PM related health consequence has not been 
extensively investigated. Previous research work by Soukup, et a l.(104) showed that the 
coarse respirable particle fraction (PM 2.5 - 10) could trigger cytokine production from 
human airway macrophages (AM). More importantly, they found that the endotoxin 
associated with these particles was mainly responsible for this phenomenon, due to the 
fact that the PM -  induced cytokine secretion required the presence of LPS binding 
protein (LBP), and cytokine production could be inhibited by polymyxin B and anti- 
CD14. Furthermore, critical involvement of TLR-4 receptor in PM 2.5 . 1 0 -  induced cell 
activation was also observed, leading to the conclusion that AM activation was most 
likely mediated by endotoxin attached to the PM -  particles. It has been shown that 
ambient urban air contains a variety of bacteria, including both Gram-positive and Gram- 
negative, at a relatively high level, even though most bacteria in the air do not grow on 
conventional media(108). However, certain bacterial components, such as endotoxin, 
could preferentially attach to the surface of the particles. The bacterial contamination on 
the surface of various particulates has not been well qualitatively and quantitatively 
measured. The biological activities between the particle itself and endotoxin 
contamination have not been well evaluated. Furthermore, the macrophage receptors and 
signaling pathways employed by the particulate or the attached endotoxin have not been 
investigated and compared.
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Because TLR-4 has been identified as the major signaling receptor for LPS, it has 
been suggested that TLR-4 is involved in LPS uptake and clearance as well. However, a 
recent study (33) found no involvement of TLR-4 in cellular LPS uptake mechanisms. 
According to their experiments using monocytes or endothelial cells, no difference of 
LPS uptake and intracellular LPS distribution was observed between TLR-4 v' and wild 
type cells. After investigating the role of CD14 and SR-A in LPS clearance and 
detoxification mechanisms, this study concluded that LPS uptake in CD 14-positive 
monocytes was predominantly mediated through a CD14 -  dependent pathway instead of 
via TLR-4. However, in CD14-negative endothelial cells, SR-A was found to play a 
critical role in LPS clearance and detoxification(33). Indeed, scavenger receptors 
expressed by macrophages have been considered to play an important role in the immune 
responses against bacterial infection by mediating ligand binding and phagocytosis. Gene 
deletion studies indicated that macrophage SR-A receptors protected mice from LPS -  
induced endotoxemia, showing that RAW264.7 cells increased SR-A transcript levels in 
response to LPS challenge
These results have led us to hypothesize that both pattem-recognition receptors, 
SR-A and TLR-4, could recognize silica and urban particles, as well as LPS as their 
ligands, and function together through a cross-talk mechanism to up-regulate immune 
responses by increasing the activity of antigen-presenting cells. Based on this hypothesis, 
we proposed that specific monoclonal antibodies could be applied to block either 
receptor, or both, on murine antigen presenting cells, followed by cell stimulation with 
the receptor ligands, including the bioactive particles and LPS. Observation of 
macrophage activation could be achieved by a number of approaches, including
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measuring macrophage cytokine secretion, or, by adding antigens (ovalbumin) and spleen 
T cells to the macrophage culture, and measuring APC activity by T cell cytokine 
production. Alternatively, studies could also be performed using macrophages from 
receptor null animals, and data could be compared to the results obtained from the studies 
using blocking antibodies to inhibit receptors on wild-type cells. Macrophage cytokine 
measurement could provide information regarding signals that activated macrophages 
send to, and eventually activate T cells. On the other hand, the T cell cytokine profile 
could also provide information regarding different T cell responses (Thl and Th2) caused 
by either receptor, or both, when certain ligands were bound. Therefore, a possible co­
functional mechanism with the two receptors and their specific ligands could be further 
determined. Previous studies(18,2T) identified positive surface expression of SR-A on 
mouse bone marrow derived macrophages, therefore this cell line was selected as antigen 
presenting cells for this in vitro study.
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Materials and Methods
Materials 
Mice
Wild-type Balb/c and C57BL/6 mice, as well as TLR-4 ''' mice in Balb/c background 
were all purchased from the Jackson Laboratory (Bar Harbor, ME). S R - A m i c e  in 
C57BL/6 background were kindly donated by Dr. Kobzik (School of Public Health, 
Harvard University). For T -  cell enrichment preparation, DO11.10 TCR transgenic mice 
in Balb/c background and OT-II TCR transgenic mice in C57BL/6 background were also 
obtained from the Jackson Laboratory. T cells from both transgenic mice express an 
ovalbumin -  specific a(3 TCR, which recognizes ovalbumin C-terminal peptide 329 -  
337 as a specific epitope presented on mouse MHCII complex. Therefore, all cells 
applied in the APC assay in this study were syngeneic. All animals were housed, 
maintained, and bred under pathogen -  free conditions at the University of Montana 
animal facility. All mice were between 8 and 10 weeks of age at the time of use.
Murine cell line and culture condition
Mouse bone marrow derived macrophages were harvested from tibia and femur of 
sacrificed mice at 8 -10 weeks of age. Cells were cultured in 75-cm tissue culture flasks 
(Coming) at about 3.0 x 107 cells/flask, and incubated in a water-jacketed incubator 
(Forma Scientific) at 37°C in the presence of 5% CO2 overnight for stromal cell 
elimination. Culture medium for mouse bone marrow derived macrophages contained 
RPM I1640 (Cellgro) supplemented with 25 mM HEPES buffer, L-glutamine, 10% fetal 
calf serum, 1.0 mM sodium pyruvate, 0.055 mM 2-Mercaptoethanol, and antibiotics (100
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U/ml penicillin G, 100 pg/ml streptomycin sulfate, and 0.25 pg/ml amphotericin B 
(Gibco BRL)). The culture medium was replaced every 3 days, and macrophage colony 
stimulating factor (MCSF) was added to the cells with fresh medium at 15 ng/mL each 
time. Cells were ready for assay after culture medium replacement and incubation for 7 
days.
Bioactive particulates and LPS
Silica (min-U-sil-5, average size 5 pm) was obtained from Pennsylvania Glass Sand 
Corporation (Pittsburgh, PA), and acid-washed to prepare a bioactive powder form. 
Urban particulate matter PM1648 (Standard Reference Material 1648) was obtained from 
the U.S Department of Commerce, National Institute of Standards & Technology 
(Gaithersburg, MD). It consists of natural atmospheric particulate matter collected in the 
St. Louis, Missouri area. The material was collected over a period in excess of 12 months 
and, therefore, is a time - integrated sample. The material was removed from the filter 
bags, combined in a single lot, screened through a fine -  mesh sieve to remove 
extraneous materials and thoroughly blended in a V -  blender, then packaged into bottles 
sequentially numbered. Lyophilized LPS powder (E. coli serotype 0111:B4) was 
purchased from Sigma (St. Louis, MO).
Endotoxin contamination on both particulates was measured with a Limulus Assay Gel 
Clot Test Kit (BioWhittaker, Walkersville, MD). Particulates were serially diluted in 
sterile water and exposed to Limulus amebocyte lysate following the manufacturer’s 
directions.
For experimental use, silica and PM1648 particles were suspended in sterile PBS (l.Ox 
solution), and sonicated for 1 minute to make a stock suspension at a concentration of 5
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mg/mL. Particles were further diluted in culture medium and used for cell stimulation at 
various final concentrations at pg/mL level. Lyophilized LPS powder was dissolved in 
sterile PBS (l.Ox solution), and filter sterilized to prepare a stock solution at a 
concentration of 1.0 mg/mL. The stock solution was further diluted in culture medium 
and used for cell stimulation with various final concentrations at ng/mL level. 
Monoclonal antibodies and isotype controls
Phycoerythrin (PE) conjugated rat anti-mouse TLR-4/MD2 (clone MTS510) was 
purchased from eBioscience (San Diego, CA). PE conjugated rat IgG2a k  isotype control 
(clone R35-95) was purchased from PharMingen (San Diego, CA). Fluorescein 
isothiocyanate (FITC) conjugated rat anti- mouse CD204 (murine scavenger receptor 
class A, clone 2F8) was purchased from Serotec (Raleigh, NC), and its isotype control, 
FITC labeled rat IgG2b k  (clone A95-1) was purchased from PharMingen. Purified rat 
anti-mouse CD16/CD32 monoclonal antibody (clone 2.4G2) that was used to block Fc 
gamma receptors during cell staining procedure was obtained from BD Biosciences (San 
Jose, CA).
Unlabeled, affinity purified rat anti-mouse TLR-4/MD2 (clone MTS510) was purchased 
from eBioscience, and affinity purified rat anti-mouse CD204 (clone 2F8) was purchased 
from Serotec for using as blocking antibodies in murine macrophage assays and APC -  T 
cell assays. The unlabeled antibody isotype controls, purified rat IgG2a k  (clone R35-95) 
and rat IgG2b k  (clone A95-1), were obtained from BD PharMingen (San Diego, CA). 
Flow cytometry (FACS Aria, Becton Dickinson)
Flow cytometry was utilized for analysis of fluorescence conjugated antibody staining 
and calculation of mean fluorescence intensity (MFI) of each sample was accomplished
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with the installed computer software (FACS Diva, BD Biosciences). MFI values were 
also applied to calculate and compare the expression levels of each cell surface marker. 
Control samples included unstained cells, as well as cells that were stained with properly 
labeled isotype control antibodies only (negative control). The instrument was calibrated 
with BD™ CompBeads Anti-Rat Ig k  (BD Biosciences) that was used to optimize 
fluorescence compensation settings for multicolor flow cytometric analyses.
Murine cytokine assays
Mouse IFN-y, IL-2, IL-10, IL-6, and IL-12 p40 levels in culture supernatants were 
quantified using OptEIA ELISA sets (PharMingen), and mouse IL-13 level was 
quantified using DuoSet ELISA Development System (R&D Systems, Minneapolis, 
MN), according to the manufacture’s protocols. Samples were tested with different 
dilution factors for different cytokine assays, based upon the amount of cytokine 
secretion and each kit’s standard curve range. ELISA microtiter plates were analyzed 
with a Spectra Max™ plate reader (Molecular Devices, Sunnyvale, CA), and the 
resulting data were processed by Soft Max™ software (Molecular Devices) using a 4 -  
parameter curve fit. Data were expressed as picograms per milliliter of medium (pg/mL).
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Methods
Verification of SR-A and TLR-4 surface expression on murine bone marrow 
derived macrophages (BMDM)
For verification of SR-A and TLR-4 surface expression on murine bone marrow derived 
macrophages, cells from wild type Balb/c mice were cultured and harvested as previously 
described. Cells were distributed into 1.2 ml microcentrifuge tubes at one million cells 
per tube, centrifuged at 4000 rpm for 3 minutes, and supernatants were removed. Cells 
were washed once with staining buffer (PBS with sodium azide and BSA), and then 
resuspended with 100 pL/tube of staining buffer containing antibodies to block Fc 
gamma receptors (CD16 and CD32) at 60.0 pg/mL. After 10 to 15 minutes incubation at 
4°C, fluorescence conjugated antibodies (clone MTS510 and 2F8) and appropriately 
labeled antibody isotype controls were added to the cells for staining at 1.0 or 2.0 pg per 
million cells. Samples were incubated at 4°C in the dark for 15 minutes. At the end of the 
incubation period, fresh staining buffer was added to the samples at 750 pL/tube, and all 
Samples were centrifuged at 4000 rpm for 3 minutes. Supernatant was removed from each 
tube, and cells were washed again by filling each tube with 500 pL fresh staining buffer 
and removing the liquid after centrifugation. After washing, cells were resuspended with 
300 pL/tube of cold (4°C) 1% paraformaldehyde (PFA), and transferred to individual 
sample acquisition tubes for flow cytometry analysis.
In order to investigate the effect of LPS, silica, and PM1648 pretreatment on cell surface 
receptor expression, BMDM cells from wild type Balb/c mice were harvested, diluted in 
culture medium and distributed into 6 -  well cell culture plates at one million cells per 
well. Stock solutions of LPS, silica, or PM1648 were prepared as described above,
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diluted in culture medium, and added to the cells. Control samples received fresh medium 
only. Cells were then incubated at 37°C in a CO2 incubator for 2, 24, or 48 hours. At the 
end of each incubation period, cells were harvested from the plate, washed, and stained 
with fluorescent antibodies as described previously.
Murine in vitro macrophage assay using mouse bone marrow derived macrophages 
(BMDM)
Mouse bone marrow derived macrophages (BMDM) from wild-type or receptor knock­
out mice were harvested, counted, and cell concentration was adjusted to 2 x 106 
cells/mL. Cell suspension was distributed into 1.2 mL centrifuge tubes, and fresh culture 
medium containing silica, PM1648, or LPS was added to the tubes at equal amounts as 
the cell suspension volume in each tube. In order to reach the desired final stimulant 
concentration in each tube, a 2-fold concentration of each stimulant was prepared for 
addition to the samples. Control samples received fresh medium only. After addition of 
stimulants, all samples were incubated on a rotator in a 37°C CO2 incubator for two 
hours. At the end of the incubation period, samples were transferred to a 96-well cell 
culture plate at 100 pL/well (1 x 105 cells per well), and another 150 pL/well of fresh 
culture medium was added to all samples. The plate was incubated for another 24 hours 
at 37°C in a CO2 incubator. At the end of the incubation period, the plate was centrifuged 
at 1500 rpm for 10 minutes, and culture supernatants (200 pL/well) were harvested and 
stored at - 20°C for further ELISA analysis. Mouse macrophage cytokines, including IL-6 
and IL-12 p40, were measured with commercial mouse cytokine ELISA kits 
(PharMingen, R&D Systems) as described previously.
In order to investigate the functions of TLR-4 and SR-A receptors on macrophage 
activation, affinity purified rat anti-mouse TLR-4/MD2 (clone MTS510) and rat anti-
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mouse CD204 (clone 2F8) were applied as blocking antibodies in this study. Certain 
samples using wild-type cells received a one - hour pre-incubation on the rotator, for 
keeping cells suspended, with or without the monoclonal antibodies specific for the 
receptors prior to stimulant addition. After incubation with or without the blocking 
antibodies and their proper isotype controls, the in vitro macrophage assay was 
performed following the same procedure as described above.
Determination of function and cooperation mechanism between TLR-4 and SR-A 
receptors with murine antigen presenting cell (APC) assay
1. Preparation of Mouse Spleen T-cell Enrichment from DO11.10 or OT-II 
TCR Transgenic Mice
Fresh mouse spleen T cells were prepared for each APC assay. Spleens were harvested 
from healthy DO 11.10 or OT-II mice, then minced and washed to prepare a fresh cell 
suspension. SpinSep™ mouse T Cell Enrichment Cocktail Kit from StemCell 
Technologies (Catalog #17061) was applied for T cell separation, following the 
commercial kit’s instructions and procedures. After the separation and washing 
procedure, the obtained T cells were counted, resuspended in mouse cell culture medium, 
and cell concentration adjusted to 4 x 106 cells/mL.
The purity of mouse T cells obtained from this separation procedure was previously 
tested by cell staining and flow cytometry analysis, and data showed that up to 97% of 
the obtained cells were positive when stained with fluorescence conjugated anti -  mouse 
CD3.
2. Mouse in vitro APC assay
Mouse BMDM from wild-type or receptor knock-out mice were harvested, counted, and 
cell concentration was adjusted to 2 x 106 cells/mL. Cells were distributed into 1.2 mL
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centrifuge tubes, and incubated for one hour with or without monoclonal antibodies 
specific for the receptors in a 37°C CO2  incubator on a rotator to prevent adherence. After 
incubation, fresh culture medium containing silica, PM1648, or LPS was added to the 
tubes at equal amount as the cell suspension volume in each tube. In order to reach the 
desired final stimulant concentration in each tube, a 2-fold concentration of each 
stimulant was prepared for addition to the samples. Control samples received fresh 
medium only. After addition of stimulants, all samples were incubated for two hours on a 
rotator in a 37°C CO2 incubator. At the end of the incubation period, samples were 
transferred to a 96-well cell culture plate at 100 pL/well (1 x 105 cells per well). 
Ovalbumin from chicken egg white (Grade V, Sigma Catalog #A5503-10G) was diluted 
in fresh cell culture medium and added to the plate at 50 pL/well to reach a final 
concentration of ovalbumin at 10 mg/mL in each well. The plate was incubated for 
another two hours at 37°C in a CO2 incubator to allow cell adherence and ovalbumin 
(antigen) uptake. After incubation, splenic T cells were added to the plate at 100 pL/well 
to give 4 x 105 T cells in each well. The plate was incubated again at 37°C in a CO2 
incubator for 48 (+ 4) hours. At the end of the incubation period, the plate was 
centrifuged at 1500 rpm for 10 minutes, and culture supernatant (200 pL/well) was 
harvested and transferred to a new 96-well plate. All samples were stored at -20°C. 
Murine cytokine secretion, including IFN-y, IL-2, IL-10, and IL-13, was measured with 
commercial mouse cytokine ELISA kits (PharMingen, R&D Systems) as described 
previously.
117
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3. Determination of receptor function and cooperative mechanism using 
blocking antibodies in mouse APC assay
In order to further determine the function of each receptor and their possible cooperative
mechanism on immune system regulation, the above two monoclonal antibodies were
again applied as inhibitors in the APC assay. Certain samples, using wild-type BMDM
cells, received a one hour pre-incubation on the rotator with or without the monoclonal
antibodies specific for the receptors, prior to stimulant addition. After incubation with or
without the blocking antibodies and their proper isotype controls, mouse APC assays
were performed following the same procedure as described above.
Various combinations of the two blocking antibodies, as well as proper isotype controls,
were tested with the murine APC assay. T cell cytokine secretion under different
experimental conditions were calculated and compared. These included APC assays
without blocking antibody, with antibody isotype controls only, with MTS510 alone, with
2F8 alone, and with both antibodies combined at appropriate concentrations as identified
from previous steps. Meanwhile, control samples were performed in each assay for
comparison. This included samples of T cells only, macrophages only, and macrophages
plus T cells with or without the presence of ovalbumin.
Statistics
For the stimulant concentration -  dependent cytokine data, a one -  way analysis of 
variance (ANOVA) was used with a post hoc comparison using a Dunnett test. Other 
analysis included one sample, one -  tailed unpaired t - test, Student -  Newman -  Keuls 
test, and Bonferroni test. Sample size for each experiment is available in the figure 
legends.
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Results
Surface expression of SR-A and TLR-4 receptors on murine bone marrow derived 
macrophages (BMDM)
In order to verify the presence of SR-A and TLR-4 receptors upon mouse BMDM (from 
wild -  type Balb/c mice), cells were stained with fluorescence conjugated monoclonal 
antibodies specific for SR-A or TLR-4, and the resulting fluorescence signals were 
analyzed with flow cytometry.
Mouse BMDM cells specifically bound the two fluorescence conjugated monoclonal 
antibodies specific for SR-A and TLR-4, respectively. When stained with 1.5 pg per 
million cells of PE-MTS510 (anti-mouse TLR-4/MD-2), mouse BMDM cells showed 
positive signals (2623 MFT) when compared with rat PE-IgG2a isotype background 
(336.1 MFI). A positive signal was also obtained when cells were stained with 1 pg per 
million cells of FITC-2F8 (anti-mouse-CD204) (7776 MFI compared with 407.8 MFI 
from antibody iso type control rat FITC-IgG2b) (Figure 4-1).
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Figure 4-1. Flow cytometry analysis of TLR-4 and SR-A expression on mouse bone 
marrow derived macrophages. Top panel: frequency histogram overlay illustrating PE 
intensity for BMDM cells stained with PE-conjugated antibody isotype only (black filled) 
or cells stained with PE- conjugated MTS510 (anti -  TLR-4, gray line). Bottom panel: 
frequency histogram overlay illustrating FITC intensity for BMDM cells stained with 
FITC-conjugated antibody isotype only (black filled) or cells stained with FITC- 
conjugated 2F8 (anti -  SR-A, gray line).
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Mouse BMDM activation with siiica, PM1648, and LPS
Mouse BMDM cells from wild-type Balb/c mice were stimulated with silica, PM1648, 
and LPS in order to investigate the biological effects of the three stimulants on mouse 
macrophage activation. Two macrophage cytokines, IL-6 and IL-12 p40, were measured 
with ELISA assays as macrophage activation markers. Dose - response curves were 
obtained with both cytokines when cells were stimulated and activated by LPS or 
PM1648 (Figure 4-2 and Figure 4-3). However, no measurable cytokines were detected 
when cells were stimulated with silica (data not shown).
121
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
300 -
o>a
250
200
150
100
50
20 40
LPS (ng/mL)
60
450
400
350
300
250
200
150
100
50
0
600 800 1000 1200200 4000
PM1648 (ug/mL)
Figure 4-2. IL-6 dose response curves obtained from mouse bone marrow derived 
macrophages (Balb/c W/T) stimulated with LPS or PM1648. Top panel: cells were 
stimulated with LPS (E. coli serotype 0111:B4) at 50, 40, 30, 20,10, 5 ,1, and 0.0 ng/mL. 
Bottom panel: cells were stimulated with PM1648 at 1000, 500, 250,125, and 0.0 
ug/mL. Data are shown as means + SD, n = 5. Statistical analysis was performed with 
one -  way ANOVA followed by Dunnetf s multiple comparison to a single control 
group. All cytokine data obtained from samples with LPS or PM1648 stimulation showed 
significant increase (p < 0.05) over control values obtained from samples treated with 
medium only.
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Figure 4-3. IL-12 p40 dose response curves obtained from mouse bone marrow derived 
macrophages (Balb/c W/T) stimulated with LPS or PM1648. Top panel: cells were 
stimulated with LPS (.E. coli serotype 0111:B4) at 50, 40, 30, 20,10, 5 ,1, and 0.0 ng/mL. 
Bottom panel: cells were stimulated with PM1648 at 1000, 500, 250,125, and 0.0 
pg/mL. Data are shown as means + SD, n = 5. Statistical analysis was performed with 
one -  way ANOVA followed by Dunned’s multiple comparison to a single control 
group. All cytokine data obtained from samples with LPS or PM1648 stimulation showed 
significant increase (p < 0.05) over control values obtained from samples treated with 
medium only.
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Effects o f blocking antibodies of TLR-4 or SR-A on macrophage activation
In order to investigate the functional roles of TLR-4 and SR-A on macrophage activation 
by LPS or PM1648, mouse BMDM cells were incubated with or without blocking 
antibodies specific for each receptor prior to LPS or PM1648 stimulation, and 
macrophage cytokine secretion was measured as previously described. Because the 
previous IL-6 and IL-12 p40 results were very similar, the remaining macrophage 
cytokine studies focused on IL-6 production. Since silica exposure did not trigger IL-6 
and IL-12 p40 secretion from mouse BMDM cells, macrophage cytokine studies using 
blocking antibodies and receptor deficient cells only focused on PM1648 and LPS 
stimulation. Investigation of receptors and signaling pathways employed by silica will be 
described in the APC assay section.
Based upon the dose response curves shown in Figure 4-2 and 4-3, LPS at 10 ng/mL and 
PM1648 at 200 pg/mL were selected, and inhibition curves were obtained using 
monoclonal anti-TLR4 (MTS510) when cells were stimulated with either LPS or 
PM1648 (Figure 4-4). However, cell activation by LPS or PM1648 were not blocked 
with monoclonal anti-SR-A (clone 2F8) (Figure 4-5). No inhibition was obtained from 
antibody isotype controls, nor was cell activation observed from samples treated with 
antibodies only (data not shown).
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Figure 4-4. Histograms illustrating blocking effect of MTS510 on cell activation by LPS and 
PM 1648 stimulation. BMDM cells from wild-type Balb/c mice were pretreated with monoclonal 
anti-TLR-4/MD-2 (MTS510) for 1 hour, then stimulated with LPS at 5.0 ng/mL (top panel) or 
PM1648 at 200 fig/mL (bottom panel), and IL-6 secretion was measured with ELISA assay. 
Samples with stimulant alone or antibody alone were included as controls. Data are shown as 
means + SD, n = 3. Statistical analysis was performed with one -  way ANOVA followed by 
Dunnett’s multiple comparison to a single control group. (*) = statistical significance atp  < 0.05 
compared to appropriate control group (uninhibited control).
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Figure 4-5. Histograms illustrating no effect of 2F8 on cell activation by LPS and 
PM1648 stimulation. BMDM cells from wild-type Balb/c mice were pre-treated with 
monoclonal anti-SR-A (clone 2F8) for 1 hour, then stimulated with LPS at 5.0 ng/mL 
(top panel) or PM1648 at 200 pg/mL (bottom panel), and IL-6 secretion was measured 
with ELISA assay. Samples with stimulant alone were included as uninhibited controls. 
Data are shown as means + SD, n = 3. Statistical analysis was performed with one -  way 
ANOVA followed by Dunnett’s multiple comparison to a single control group 
(uninhibited control). Statistical analysis revealed no significant difference in IL-6 levels 
between sample groups with and without 2F8 pretreatment.
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IL-6 production using BMDM cells from TLR-4 " Balb/c mice
In order to investigate the role of TLR-4 receptor in signaling pathways for BMDM 
activation by LPS and PM1648, IL-6 production was measured using BMDM cells from 
TLR-4 "A Balb/c mice. Cells from wild-type Balb/c mice were included in the assay as a 
positive control. Data obtained from this study showed that IL-6 secretion using BMDM 
cells from TLR-4 'A mice was significantly reduced with LPS stimulation, compared to 
the results obtained from wild-type BMDM cells (Figure 4 -  6). Furthermore, when 
stimulated with PM1648, IL-6 production at each concentration of PM1648 was 
decreased by approximately 50% using BMDM cells from TLR-4 "A mice, compared to 
the wild-type cells.
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Figure 4-6. Line graph illustrating IL-6 release from TLR-4 deficient mouse BMDM 
cells stimulated with LPS or PM1648. Mouse BMDM from TLR-4 _/' (filled squares) or 
wild type Balb/c (empty triangles) mice were stimulated with LPS at 20,10, 5, 2.5, 0 
ng/mL (top panel) or PM1648 at 1000, 500, 250,125, 0 pg/mL (bottom panel). IL-6 
secretion was measured with ELISA assay. Data are shown as means + SD, n = 3. 
Statistical analysis by two - way ANOVA followed by post test of Bonferroni. All 
cytokine data obtained from TLR-4 cells, with either LPS or PM 1648 stimulation, 
showed significant decrease (p < 0.05) compared to control values obtained from wild 
type BMDM cells.
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IL-6 production using BMDM ceils from SR -A ' ' C57BL/6 mice
In order to further test the role of SR-A in response to LPS and PM1648 stimulation, 
BMDM cells from SR-A_/' (C57BL/6) mice were utilized to measure IL-6 production. 
Cells from wild-type C57BL/6 mice were also included as a positive control. IL-6 
secretion from SR-A‘ ‘ BMDM cells with LPS stimulation was apparently increased as 
compared to results obtained from wild-type BMDM cells, even though the amount of 
increase did not achieve statistical significance (Figure 4-7). However, at each 
concentration of PM1648 used for cell stimulation, IL-6 production from SR-A‘" cells 
was significantly increased compared to the secretion from wild-type cells (Figure 4-7)
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Figure 4-7. Histograms illustrating IL-6 production from wild type and SR-A ' '  mouse 
BMDM cells stimulated with LPS or PM1648. Mouse BMDM from SR-A '/_ (empty 
bars) or wild type C57BL/6 (filled bars) mice were stimulated with LPS at 20,10, 5.0 
ng/mL (top panel) or PM1648 at 500, 250,125 pg/mL (bottom panel). IL-6 secretion was 
measured with ELISA assay. Data are shown as means + SD, n = 3. Cytokine data 
obtained from SR-A 'A cells with PM1648 stimulation (bottom panel) showed significant 
difference (p < 0.05) over control values obtained from wild type BMDM cells, by one 
tailed, unpaired t - test. (*) = statistical significance atp < 0.05.
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Murine in vitro APC assay
Murine in vitro APC assays were performed using mouse BMDM cells from wild-type 
Balb/c mice, as antigen presenting cells, to investigate the biological effects of silica, 
PM1648 particulates, and UPS on APC activation. Four mouse T cell cytokines, 
including IFN-y, IL-2, IL-10, and IL-13, were quantified, as APC activation markers, 
with ELISA assays.
The data in Figure 4-8 show the results of IFN-y and IL-2 production, the two Thl 
cytokines, following exposure to the three stimulants. Silica at 200 pg/mL increased IFN- 
y secretion by 105% ± 16%, indicating an up-regulation of the APC activity. However, 
PM1648 exposure at the same concentration showed no significant effect on IFN-y 
production. On the other hand, although LPS at 10 ng/mL did tend to decrease the 
amount of IFN-y production by calculating the mean percentage of decrease, statistical 
analysis revealed no significant changes in IFN-y levels compared to the control samples. 
Similar results were obtained with measurement of IL-2 secretion.
A different activation pattern was obtained when mouse Th2 cytokines, IL-10 and IL-13, 
were quantified (Figure 4-9). All three stimulants increased the amount of both IL-10 and 
IL-13 secretion, showing an up-regulation of APC activity.
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Figure 4-8. Histograms illustrating percentage of Thl cytokine increase / decrease from 
BMDM cells exposed to silica, PM1648, or LPS. BMDM from wild-type Balb/c mice 
were treated with silica (200 pg/mL), PM1648 (200 pg/mL), or LPS (10 ng/mL) for 2 
hours, followed by addition of albumin and T cells from DO11.10 mice. After incubation 
for 48 hours, cytokine production was measured and the percentage of increase / decrease 
compared to control samples was calculated. Top panel: IFN-y production; Bottom panel: 
IL-2 production. Data are shown as mean + SD, n=3. (*) = statistical significance atp  < 
0.032 compared to appropriate control, by one -  sample t test.
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Figure 4-9. Histograms illustrating percentage of Th2 cytokine increase / decrease from 
BMDM cells exposed to silica, PM1648, or LPS. BMDM from wild-type Balb/c mice 
were treated with silica (200 pg/mL), PM1648 (200 pg/mL), or LPS (10 ng/mL) for 2 
hours, followed by addition of albumin and T cells from DO11.10 mice. After incubation 
for 48 hours, cytokine production was measured and the percentage of increase compared 
to control samples was calculated. Top panel: IL-10 production; Bottom panel: IL-13 
production. Data are shown as mean + SD, n=3. (*) = statistical significance at p  < 0.032 
compared to appropriate control, by one -  sample t test.
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Inhibition of APC activation by LPS with monoclonal anti-SR-A (clone 2F8) and 
anti-TLR-4 (clone MTS510)
Blocking antibodies were used to determine the functions and possible cooperative 
mechanisms between TLR-4 and SR-A receptors for up-regulating APC response to LPS 
exposures. Because LPS exposure mainly increased Th2 cytokines from Balb/c BMDM, 
this study therefore focused on IL-13 and IL-10 production. When BMDM cells from 
wild type Balb/c mice were pretreated with MTS510 at 10 pg/'mL, 5.0 pg/mL, or 2.5 
pg/mL, followed by LPS stimulation at 10 ng/mL, a reduction of IL-13 secretion was 
observed and an inhibition curve was obtained based on the antibody concentrations 
applied. However, when cells were pretreated with 2F8 (2.0,1.0, or 0.5 pg/mL) to block 
the SR-A receptor, no significant inhibition effect was observed (Figure 4-10). The 
antibody isotype controls were included in the assay and showed no effects. Similar 
inhibition results were also obtained with IL-10 measurement (data not shown).
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Figure 4-10. Histograms illustrating percent inhibition of IL-13 secretion from BMDM 
cells exposed to LPS. BMDM cells from wild type Balb/c mice were pretreated with 
MTS510 (10, 5.0, or 2.5 pg/mL) or 2F8 (2,1, or 0.5 pg/mL) for 1 hour, followed by LPS 
stimulation atlO ng/mL for 2 hours. After incubation with ovalbumin and spleen T cells 
from DO11.10 mice for 48 hours, IL-13 production was measured and percentage of 
inhibition, compared to uninhibited controls, was calculated. Data are shown as mean + 
SD, n=3. (*) = statistical significance at p < 0.032 compared to appropriate control, by 
one -  sample t test.
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Inhibition of APC activation by PMI648 with monoclonal anti-SR-A (clone 2F8) 
and anti-TLR-4 (clone MTS510)
When cells were pretreated with the same antibodies but exposed to PM1648, an 
inhibition pattern similar to LPS exposure was obtained. When BMDM cells from wild- 
type Balb/c mice were pretreated with MTS510 at 10 pg/mL, 5.0 pg/mL, or 2.5 pg/mL, 
followed by PM1648 stimulation at 200 pg/mL, a reduction of both IL-13 and IL-10 
secretion was observed. Again, no significant inhibition effect was observed with 
PM1648 stimulation after cell pretreatment with monoclonal anti-SR-A 2F8 (2.0,1.0, or 
0.5 pg/mL) (Figure 4-11).
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Figure 4-11. Histograms illustrating percent inhibition of IL-13 secretion from BMDM 
cells exposed to PM1648. BMDM cells from wild-type Balb/c mice were pretreated with 
MTS510 (10, 5.0, or 2.5 pg/mL) or 2F8 (2, 1, or 0.5 pg-mL) for 1 hour, followed by 
PM1648 stimulation at 200 pg/mL for 2 hours. After incubation with ovalbumin and 
spleen T cells from DO11.10 mice for 48 hours, IL-13 production was measured and 
percentage of inhibition compared to uninhibited controls was calculated, compared to 
uninhibited control samples. Data are shown as mean ± SD, n=3. (*) = statistical 
significance at p<  0.032 compared to appropriate control, by one -  sample t test.
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Inhibition of APC activation by silica with monoclonal anti-SR-A (clone 2F8) and 
anti-TLR-4 (clone MTS510)
A different inhibition pattern was obtained when BMDM cells from wild type Balb/c 
mice were pretreated with the same antibodies but exposed to silica. Because silica 
stimulation increased both Thl and Th2 cytokines with in vitro APC assay using BMDM 
cells from Balb/c mice, this inhibition study was measured with both Thl and Th2 
cytokine productions. When determined with Thl cytokines (IFN-y or IL-2), MTS510 or 
2F8 pretreatment each decreased cytokine secretion from BMDM cells. More 
importantly, when BMDM cells were pretreated with the combination of the two 
antibodies, an increased inhibition was observed. When inhibition was measured with 
Th2 cytokines (IL-10 and IL-13), similar inhibition patterns were obtained, showing that 
each antibody inhibited APC activation by silica exposure, and the percentage of 
inhibition was increased when both antibodies were applied (Figure 4-12).
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Figure 4-12. Histograms illustrating percentage of inhibition obtained from cell 
pretreatment with MTS510, 2F8, or with antibody combination. BMDM cells from wild 
type Balb/c mice were pretreated with MTS510 atlO pg/mL. 2F8 at 2 pg/mL, or with 
combination of both antibodies for 1 hour, followed by silica exposure at 200 pg/mL for 
2 hours. After incubation with ovalbumin and spleen T cells from DO11.10 mice for 48 
hours, IFN-y (top panel) and IL-13 (bottom panel) production was measured and 
percentage of inhibition was calculated, compared to uninhibited control samples. Data 
are shown as mean + SD, n=3. (*) = statistical significance atp <  0.05 by Dunntte test. 
All inhibition percentage showed significant difference (p < 0.05) compared to 
uninhibited controls. Percentage of inhibition obtained from cell pretreatment with 
antibody combination showed significant difference (p < 0.05) over inhibition percentage 
obtained from cell pretreatment with each individual antibody.
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Murine in vitro APC assays using BMDM cells from wild-type and TLR-4' ' Balb/c 
mice
In order to further investigate the role of the TLR-4 receptor in APC activation by silica, 
PM1648 particulates, and LPS stimulation, murine in vitro APC assays were performed 
using mouse BMDM cells from wild type compared to TLR-4 Balb/c mice. IL-13, a 
Th2 cytokine was selected as the activation marker for this assay since only Th2 -  
dominant responses to LPS and PM1648 were observed (Figure 4-9). Data showed that 
IL-13 production was significantly decreased from TLR-4' ' cells stimulated with LPS, 
silica, or PM1648, compared to IL-13 secretion from wild type cells (Figure 4-13).
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Figure 4-13. Histograms illustrating IL-13 production from wild-type and TLR-4'/_ 
mouse BMDM cells stimulated with LPS, silica, or PM1648. Mouse BMDM cells from 
TLR-4 'h (empty bars) or W/T Balb/c (filled bars) mice were stimulated with LPS (10 
ng/mL), silica (200 pg/mL), or PM1648 (200 pg/mL). After incubation with OVA 
(antigen) and spleen T cells from DO11.10 transgenic mice in Balb/c background for 48 
hours, IL-13 secretion was measured with ELISA assay. Data are shown as means + SD, 
n = 3. (*) = statistical significance atp <  0.05, by one tailed, unpaired t - test.
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Murine in vitro APC assay using BMDM cells from wild-type and SR-A ' ' C57BL/6 
mice
In order to further investigate the role of SR-A receptor in mouse APC activation with 
silica, PM1648 particulates, and LPS stimulation, murine in vitro APC assays were 
performed using mouse BMDM cells from wild type or SR-A " in the background of 
C57BL/6 mice. Two types of mouse T cell cytokines, IFN-y (Thl) and IL-13 (Th2), were 
selected as activation markers for this assay, and were quantified with ELISA assays. No 
statistical significance was achieved between wild type and SR-A" " cells with IFN-y 
production when cells were stimulated with LPS at 10 ng/mL, even though the mean of 
IFN-y production did tend to lessen from SR-A" " cells. When cells were stimulated with 
silica, IFN-y production from SR-A"7'cells was significantly decreased compared to the 
wild-type cells. The two types of cells produced almost the same amount of IL-13 when 
stimulated with LPS at 10 ng/mL. Compared to the wild-type cells, IL-13 production was 
significantly decreased from SR-A"7 cells with silica stimulation at 200 pg/mL, but not 
with PM1648. PM1648 stimulation did tend to increase the average IL-13 secretion from 
SR-A'7' cells, but again the difference did not achieve statistical significance when 
compared to the wild type cells (Figure 4-14).
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Figure 4-14. Histograms illustrating T cell cytokine production from wild type and SR- 
A mouse BMDM cells stimulated with LPS, silica, or PM1648. Mouse BMDM cells 
from SR-A'' (empty bars) or W/T C57BIV6 (filled bars) mice were stimulated with LPS 
(10 ng/mL), silica (200 pg/mL), or PM1648 (200 pg/mL). After incubation with OVA 
(antigen) and spleen T cells from OT-II transgenic mice in C57BL/6 background for 48 
hours, IFN-y (top panel) and IL-13 (bottom panel) secretion was measured with ELISA 
assays. Data are shown as means + SD, n = 3. (*) = statistical significance atp  < 0.05, by 
one tailed, unpaired t - test.
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Discussion
TLR-4 and SR-A are two types of pattern recognition receptors expressed on 
antigen presenting cells. LPS has been identified as a ligand for both receptors, and it has 
been known that LPS signals through TLR-4 receptor. LPS exposure could result in 
macrophage activation and cytokine secretion, followed by activation of the adaptive 
immune system. On the other hand, different types of bioactive particles can lead to 
different health consequences. A previous study has shown involvement of SR-A in silica 
-  induced apoptosis using Chinese hamster ovary cells transfected with SR-A(24). Several 
recent controlled -  exposure studies in humans indicated that exposure to certain types of 
PM particles could induce inflammatory responses(20,22’23,25\  Alveolar macrophage 
(AM) apoptosis induced by airborne particulate matter PM1648 was reported to be 
mediated through SR-A(112). Moreover, exposure to airborne fine particulate matter 
PM2.5 was clinically related to respiratory disorders, such as asthma morbidity (111). 
However, the molecular mechanistic basis for the observed health effects induced by the 
bioactive particles is not yet completely understood. This subject is likely to become 
more important as the research community focus more on the field of molecular 
epidemiology for the bioactive particulate induced health consequences.
Our results demonstrated that BMDM exposure to bioactive particulates and LPS 
could increase their APC activity in vitro, as measured by Th cytokine production. 
Meanwhile, since selective blocking of TLR-4 or SR-A receptors with monoclonal 
antibodies was able to inhibit certain T cell cytokine secretion, together with cytokine 
data obtained from TLR-4 or SR-A deficient animals, we have demonstrated that 
signaling pathways for LPS and bioactive particulates, including silica and PM1648,
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were mediated through different receptor combinations. Silica uses both SR-A and TLR- 
4 to activate APC efficiently, while both LPS and PM1648 use TLR-4 for macrophage 
activation. However, our further investigations suggested that LPS and PM1648 might 
bind to SR-A as receptor ligands, even though microphage activation appeared to be 
mediated through TLR-4 and maybe some other receptors. Furthermore, by using SR-A 
deficient cells, our data also suggested that SR-A might function as a negative regulator 
in BMDM activation by LPS and PM1648.
LPS has been used as a stimulant control in this project, and data obtained from 
the current study was in agreement with previous findings from human studies (see 
Chapter 2 and 3). LPS - stimulated macrophage cytokine production (IL-6 and IL-12 p40) 
was dependent on TLR-4 since mouse BMDM cells from TLR-4" Balb/c mice did not 
respond to LPS stimulation (Figure 4-6). However, both wild type and SR-A'7 BMDM 
cells from C57BL/6 mice were activated to a similar extent in response to LPS 
stimulation, and indeed, SR-A7' cells tended to have a higher cytokine production than 
the wild-type cells (Figure 4-7). This finding indicated that SR-A might play a role of 
negative regulation on cell activation by LPS. Therefore, even though LPS has been well 
identified as a ligand for direct binding to both cell surface receptors, our results 
indicated that BMDM activation by LPS was mediated through TLR-4 receptor, and SR- 
A might function as a negative regulator in this process, possibly by its function of LPS 
clearance and detoxification. Data from murine in vitro APC assays with selective 
monoclonal antibody inhibition confirmed the above finding. BMDM cells from wild- 
type Balb/c mice mainly produced Th2 - associated cytokines (IL-10 and IL-13) in 
response to LPS challenge. Pre-incubation of TLR4 -  specific monoclonal antibody
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MTS510 with the cells resulted in reduction of cytokine production, and an antibody dose 
-  dependent inhibition curve was obtained (Figure 4-10, top panel). Meanwhile, when 
SR-A specific monoclonal antibody 2F8 was applied in the same procedure, no inhibition 
effect was observed (Figure 4-10, bottom panel). Therefore, with the APC inhibition 
assay data we again demonstrated that between the two receptors, BMDM activation by 
LPS was mediated through TLR-4.
Available studies have indicated that LPS and its lipid A component, as well as 
synthetic MPL adjuvant whose structure was based on active lipid A component, had the 
capacity to mainly induce a Thl immune response, characterized by cell-mediated 
immunity and production of Thl cytokine (IFN-y)(31). However, with our mouse in vitro 
APC assay using wild type Balb/c BMDM cells, our data showed that LPS stimulation 
mainly triggered a Th2 response (Figure 4-8 and 4-9). A previous study conducted at 
Yamanouchi Pharmaceutical Corporation (Ibaraki, Japan) provided a possible 
explanation for the conflicting results, and suggested that the addition of ovalbumin 
(OVA) to the assay system could play a role in determining the different Th responses 
<26). Their study investigated the effect of antigen dose on immune response, with Balb/c 
and C5 7BL/6 mice being sensitized by aluminum hydroxide gel (alum) -  precipitated 
OVA then challenged with aerosolized OVA. Their data showed that sensitization with 
different doses of OVA could elicit different Th responses. Sensitization with high dose 
OVA mainly induced Thl -  type cytokine production in the lungs of C57BL/6 mice, 
whereas Balb/c mice mainly generated Th2 -  type cytokines in response to the same 
sensitization. More interestingly, they found that a wide range of OVA sensitization dose 
(100 ng -  1 mg) did not affect the types of Th responses from splenocyte cultures of
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either moue type. A Thl type response was always triggered in C57BL/6 mice, whereas 
a Th2 type response was always observed from Balb/c mice when their splenocyte 
cultures were tested in vitro. This study therefore concluded that C57BL/6 and Balb/c 
mice had different susceptibilities to OVA -  sensitization because the antigen dose range 
could determine the types of Th responses in the lungs of the two different groups of 
mice, but independent of the splenic Th cytokine responses(26). With one of our murine 
APC assay systems using BMDM cells from Balb/c mice, OVA, at a high concentration 
of 10 mg/mL, was added to the assay culture system with spleen T cells from transgenic 
DO11.10 mice in Balb/c background. Therefore, such a culture system could well exhibit 
a Th2 dominant response to LPS challenge. On the other hand, with another APC assay 
system using C57BL/6 BMDM cells and spleen T cells from transgenic OT-II mice in 
C57BL/6 background, we obtained both Thl and Th2 cytokines in response to LPS 
stimulation (Figure 4-14).
Our data also indicated that PM1648 could up-regulate Th2 cytokine production 
(IL-10 and IL-13), but it had no significant effect on Thl cytokine secretion from mouse 
in vitro APC assays, with either Balb/c -  DO11.10 or C57BL/6 -  OT-II systems. These 
results were very similar to a previous report showing that PM1648 could increase IL-4 
production from human alveolar macrophage (HAM) and peripheral blood monocytes, 
but did not affect Thl cytokines(22). More importantly, due to the absence of SR-A on 
blood monocytes, their data also suggested that PM1648 might bind and signal through 
some other cell surface receptors for inducing Th2 cytokine production. This proposal 
may provide explanations for the above phenomenon that PM1648 exposure primarily 
triggers a Th2 cytokine response and it can affect both HAM and peripheral blood
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monocytes ('22\  Similar as LPS, we found that SR-A might play a role in negatively 
regulating cell activation by PM1648. This result is apparently in agreement with the 
previous findings. With both APC and macrophage cytokine assays, we also 
demonstrated that one of the signaling pathways for BMDM activation by PM1648 was 
TLR-4 - dependent.
The SR-A blocking antibody 2F8 had no inhibitory effect towards Th2 cytokine 
production induced by PM1648 (Figure 4-11, bottom panel). In contrast, MTS510, the 
TLR4 -  specific monoclonal antibody, inhibited PM1648 - induced Th2 cytokine 
production up to approximately 45% (Figure 4-11, top panel). Similar results were 
obtained from both macrophage cytokine assays and in vitro mouse APC assays using 
receptor deficient cells. Both wild type and SR-A '- cells produced macrophage cytokines 
(Figure 4-7, bottom panel) and Th2 -  associated cytokines (Figure 4-14, bottom panel) in 
response to PM1648 stimulation. However, PM1648 challenge induced significantly less 
macrophage cytokines (Figure 4-6, bottom panel) as well as Th2 cytokines (Figure 4-13) 
from TLR-4" cells compared to the wild type cells. Taken together, these data clearly 
indicated that PM1648 signaling was in part mediated through TLR-4 receptor. However, 
as previous studies suggested (112\  some other scavenger receptors, such as MARCO, 
might be involved in PM1648 signaling since BMDM activation by PM1648 exposure 
was not completely blocked by using either blocking antibody (MTS510) or TLR-4 
deficient cells.
The possibility of cell activation by LPS contamination on PM1648 particles was 
taken into consideration. Residual endotoxin on PM1648 particulates was detected with a 
Limulus assay at 1.04 EU/mg. However, with the PM1648 concentrations used for cell
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stimulation in this study, the concentration of possible LPS contamination was at low 
pg/mL levels, from 1.3 to 5.2 pg/mL. Previous results (Wang, et al, 1997) have shown 
that LPS stimulation at such low concentrations would not be able to activate 
macrophage cells and induce cytokine secretion. Therefore, the low level of LPS 
concentration on PM1648 suggested that BMDM cells were not activated by LPS 
contamination, but rather the stimulation was from some other component of PM1648.
Interestingly, PM1648 stimulation resulted in a significant increase of 
macrophage cytokine production, with a dose -  dependent manner, from SR-A ‘ BMDM 
cells compared to wild type C57BL/6 BMDM cells (Figure 4-7, bottom panel). As shown 
in the same figure, a similar cytokine increase was obtained when the SR-A ~!' cells were 
stimulated with LPS, even though the increase in this case did not reach statistical 
significance. A similar observation was obtained from a previous study(13), showing that 
instead of activating a cytokine response, SR-A -  mediated LPS uptake actually 
suppressed cytokine production in response to LPS exposure, suggesting that LPS 
binding to SR-A might result in various consequences, determined by the extent of 
activation of the macrophages. As described earlier, our data also suggested that SR-A 
might play a role in negatively regulating mouse BMDM activation in response to LPS 
and PM1648, probably due to the SR-A mediated endotoxin and particle clearance.
However, another potential role of SR-A receptor, which was just described in a 
recent study (Jozefowski and Kobzik, 2004), might also be involved in the above 
phenomenon. This study found that SR-A on murine macrophages might be able to affect 
the different directions of Th responses by generating H2O2 to suppress IL-12 production 
from macrophages while the cell surface SR-A receptor was engaged with ligands. A
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similar observation was obtained from a recent study (Migliaccio, Holian, et al. 
unpublished data), showing that with the presence of ovalbumin in the culture system, IL- 
12 production was significantly decreased from BMDM cells (from w/t Balb/c mice) 
treated with silica, a known ligand for SR-A receptor. This may help to explain the 
tendency of PM1648 exposure to bias a Th2 cytokine response in our APC assays, with 
either Balb/c or C57BL/6 cells. Meanwhile, it may also help to explain the increase of 
macrophage cytokine that we obtained with SR-A "A BMDM cells. Even though our 
current study indicated that both LPS and PM1648 did not signal through SR-A receptor 
for APC activation, SR-A has been well known to play a role in immune response against 
bacterial infection by mediating pathogen binding and phagocytosis, and LPS has been 
identified as a ligand for direct binding with SR-A. Similarly, our present data also 
suggested that PM1648 particulate might be involved in direct binding with SR-A as 
well. The engagement of LPS and PM1648 to cell surface SR-A receptor could result in 
generation of H2O2 followed by suppression of certain cytokine productions, which might 
include both IL-12 and IL-6. With the SR-A/_ cells, we propose that due to the absence of 
surface SR-A receptor and the receptor -  ligand engagement, LPS and PM1648 treatment 
did not result in H2O2 production, therefore the SR-A "A macrophages could operate free 
of the H2O2 suppressing influence, enhancing the production of IL-12 and IL-6 as 
compared to the wild type cells.
Investigation of surface receptors for silica signaling pathways rendered different 
results. Both Thl and Th2 responses were obtained when BMDM cells from wild type 
Balb/c mice were treated with silica (Figure 4-8 and 4-9). A different inhibition pattern 
was obtained with APC antibody - inhibition assays. MTS510 and 2F8 each
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demonstrated an inhibitory effect on cell activation by silica, when activation was 
measured with either Thl or Th2 cytokines (Figure 4-12). When cells were pretreated 
with the combination of both antibodies, an additive effect of inhibition was observed 
(Figure 4-12). Similar results were obtained from APC -  T cell assays using receptor 
deficient APC cells, showing significant reductions of both IFN-y and IL-13 from SR-A' 
BMDM cells (Figure 4-14) and a reduction of IL-13 from TLR-4'' BMDM cells as 
antigen presenting cells (Figure 4-13). Taken together, the current study indicated that 
both TLR-4 and SR-A receptors play a role in silica signaling pathways for APC 
activation.
Limulus assays were again performed for detection of residual endotoxin on silica 
particulates in order to confirm the above conclusion that silica signals through both 
receptors. No detectable amount of LPS was found on silica particulates with the Limulus 
assay (data not shown). In addition, the macrophage cytokine assays performed in the 
present study found no measurable amount of cytokines (IL-6 and IL12 p40) from cells 
stimulated with silica, whereas dose response curves were obtained from cells activated 
by LPS stimulation (Figure 4-2). Therefore, macrophage cytokine secretion would be 
well expected if a significant amount of LPS contamination existed on silica. Taken 
together, these data confirmed the Limulus assay results, indicating that no LPS 
contamination on silica particles was activating macrophages.
However, the low amount of macrophage cytokine secretion, below detectable 
levels of ELISA assays, from silica -  treated BMDM cells raises another question. Such a 
low amount of cytokine production was obtained from cells of wild-type mice as well as 
receptor deficient mice, from either Balb/c or C57BL/6 background. Since silica
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stimulation did trigger both Thl and Th2 responses in APC -  T cell assays, the low 
macrophage cytokine data suggested that macrophages activated by silica treatment sent 
signals other than cytokines, IL-6 and IL-12 p40 in this case, to T cells and eventually 
activated T cells. Recent studies (Hamilton, et al, unpublished data) supported this 
hypothesis. In their experiments following the APC -  T cell assay protocol, BMDM cells 
from wild-type Balb/c mice were incubated with OVA and spleen T cells in routine cell 
culture plates. However, insertion of “filter trans-wells” that contained BMDM cells 
being treated with silica to the culture plate wells did not increase, in some cases even 
decreased, T cell cytokine production (IFN-y and IL-13) compared to the wells without 
“trans-well” insertions. Since “trans-wells” only allow soluble materials to pass through 
the filter, their data therefore indicated that signal factors, perhaps cell surface bound, 
other than soluble cytokines from silica - treated APC cells contributed to T cell 
activation. Further studies are required for investigation of signal factors sent by BMDM 
cells stimulated with silica.
In conclusion, the present study demonstrated that silica uses both TLR-4 and SR- 
A receptors for signaling through a possible “cross -  talk” cooperative mechanism in 
order to activate macrophages efficiently, while endotoxin and PM1648 use TLR-4 for 
macrophage activation, even though SR-A might be involved in negative regulation of 
the cell activation process, as well as in mediating endotoxin and particulate direct 
binding and clearance. Such findings might be well related to the different health 
implications caused by silica and PM1648 exposure, as silica has been related mainly to 
fibrosis in the lung, whereas PM exposure has been known to exacerbate asthma. The 
different receptor combinations, signaling mechanisms and pathways employed by the
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two particulates for activating macrophages, which in turn initiate innate and adaptive 
immune responses, might contribute differently to lung pathogenicity upon exposure to 
the two different bioactive particulates, and might lead to different health consequences.
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CHAPTER 5 
Conclusions & Future Studies
The innate immunity is the first line of host defense system that enables multi- 
cellular organisms to rapidly and efficiently respond to infectious agents. One of the most 
important components of this quick -  reaction force is a sensitive and accurate detection 
system, that consists of a set of immune cells and receptors expressed on the surface of 
these cells that can recognize particular molecular features associated with the pathogens 
and initiate signal transduction. Therefore, these receptors are named as pattern 
recognition receptors (PRR). Antigen presenting cells (APC), including macrophages and 
dendritic cells, express a wide range of PRRs involved in pathogen recognition, 
phagocytosis, antigen destruction or presentation to T cells, as well as induction of 
adaptive immunity. The current study focused on the signaling mechanisms and potential 
ligands for two types of PRRs, Toll-like receptor 4 (TLR-4) and scavenger receptor (SR- 
A).
TLRs recognize a variety of structural components that are unique and highly 
conserved in pathogens. The interactions between TLR and its specific ligands activate 
the host defense system with both innate and adaptive immune responses. After TLR -  
mediated recognition of pathogen components, a variety of immune cell types may be 
activated to initiate a series of defensive actions against the invading pathogen, including 
phagocytosis, production of reactive oxygen intermediates, up-regulation of MHC 
complex and surface co-stimulatory molecules, and secretion of inflammatory cytokines. 
These cytokines may activate natural killer cells, and furthermore, they may initiate and 
direct the adaptive immune system. Thus, TLRs possess critical functions in innate
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immunity with short -  term anti-microbial effects, as well as in adaptive immunity with 
long -  term effects and immunological memory(31). In addition, recent studies have 
revealed relationship between vaccine adjuvant activity and TLR functions, indicating 
that most vaccine adjuvants function via TLR - mediated recognition and signaling 
pathways. Therefore, development of TLR agonists and antagonists as potential adjuvant 
candidates has become a novel and effective approach in the adjuvant research field, 
since it has been clear that the initiation and manipulation of innate immune responses 
through certain TLRs could play a critical role in a successful vaccination with long - 
term protective immunity (33> 34).
So far, the known ligands that signal through TLRs are mainly from exogenous 
origins, but there are reports of endogenous ligands as well as intracellular ligand -  
receptor interactions rather than surface engagement through TLRs(37,38). Among the 
many identified TLR ligands, LPS from Gram-negative bacteria is one of the best 
understood ligands for TLR-4 receptor, and the mechanism and pathways for LPS 
signaling through TLR-4 to initiate innate immune responses have been illustrated(28'29, 
30). In addition, MPL adjuvant, developed by Ribi ImmuneChem Research Inc., is an 
immunoactive lipid A fraction derived from the LPS of Salmonella Minnesota R595 
through sequential steps of acid and base hydrolysis. Pre-clinical and clinical studies 
focusing on the functional mechanism of MPL adjuvant have shown that the 
immunological activity of MPL adjuvant was mediated through TLR-4 receptor, which is 
very similar to its parent molecule LPS. Based on the experience and knowledge from 
MPL studies, scientists at Corixa Corporation developed a library of novel synthetic 
glycolipids, the so-called “AGP” compounds. More importantly, some AGP compounds
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have shown very similar adjuvant activities as those induced by MPL, suggesting that the 
synthetic compounds and MPL adjuvant might share the same or similar intracellular 
signaling pathways.
The adjuvant activity, immune potency and efficacy, as well as clinical safety of 
MPL adjuvant have been well evaluated during the past 15 years in human clinical trials 
with various disease models, including cancer, autoimmune diseases and infectious 
diseases. Study results indicated that MPL adjuvant was safe and efficacious for use in 
human vaccines in these clinical trials. Meanwhile, pre-clinical studies also demonstrated 
that some leading AGP compounds were as effective as MPL adjuvant for certain disease 
models, and in some cases even improved clinical safety due to their synthetically 
designed chemical structures and high purity(7,31).
In order to further characterize immunological mechanisms for AGP activity, it 
was first necessary to evaluate AGP biological potencies with a consistent and re­
producible assay system, and identify certain connections between AGP structural 
characteristics and its biological potency. Chapter Two of this study focused on the 
development of a reproducible in vitro cell assay system using human monocytic cell 
lines MonoMac-6 and U937, and this system was applied for evaluation of AGP 
biological potencies. Data reported in Chapter Two are in excellent agreement with 
previous work accomplished at Corixa Corporation using in vitro or in vivo models, 
indicating that secondary fatty acid chain length played an important role in AGP 
potency. AGP compounds that carry 9,10,11, or 12 carbons in their secondary fatty 
acids were immunologically much more potent compared to compounds with either short 
( 6 - 8  carbons) or long (14 carbons) secondary fatty acid chains. Compounds with ten-
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carbon fatty acids in all three secondary positions showed the highest biological potency 
in numerous evaluation studies. Such results suggested that certain structural parameters 
had significant effects on AGP biological activity. Critical structural characteristics, such 
as acyl chain length, spacing, distance, and the resulting packing tightness in the solution, 
could directly affect compound solubility, stability, and its energetically favored or 
disfavored conformation in aqueous solution, therefore leading to different immune 
stimulating capacities. The conformational changes resulting from acyl chain length / 
spacing would be involved in the specificity of AGP - induced immune responses as well, 
since structural flexibility would affect the binding access of cell surface receptors and 
molecules to the compounds. Hence, manipulation of certain structural parameters could 
have a critical impact on a compound’s adjuvant activities. Because AGPs are synthetic 
chemical compounds, their structures can be designed and modified for clinical and 
medicinal needs. Certain structural parameters can be identified as key components that 
are responsible for compound biological potency, the ability to bias and direct immune 
responses, as well as safety profiles. Such characterization and development work would 
help further discovery of immune stimulants and adjuvants that could become leading 
candidates for new clinical products with high efficiency and specificity, but with low 
toxicity and fewer side effects.
Chapter Three explored the TLR-4 signaling functions on AGP compound 
activity through biological inhibition assays, direct binding assays, as well as binding 
inhibition studies. By using monoclonal anti-human-TLR4 (clone HTA125), we 
demonstrated that both MPL adjuvant and AGP compounds were signaling through TLR- 
4 receptor, similar to their parent molecule, LPS.
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Even though TLR-4 receptor has been well recognized as the primary recognition 
molecule for LPS, the detailed and actual mechanism of ligand binding and signaling 
through the receptor remains unclear. In addition, although TLR-4 is a pattern recognition 
receptor, like scavenger and mannose receptors, its functions on LPS clearance are 
unknown. The current understanding of the signaling mechanism involves LPS binding 
protein (LBP), CD14, and a small glycosylated protein, MD-2. LBP first binds and 
transfers LPS to CD 14 for signal complex formation, which in turn initiates intracellular 
signaling of LPS via membrane TLR-4. Additional evidence also suggested that MD-2 
was required in the TLR-4 signaling complex for optimal function(33). Our LPS direct 
binding assay indicated that addition of soluble CD14 and LBP was required for Alexa- 
LPS direct binding to cell surface, which was consistent with the above description. The 
inhibition data reported in Chapter Three, using unlabeled LPS and HTA125 to inhibit 
Alexa-LPS direct binding to human MonoMac-6 cells, indicated a two-step binding 
mechanism of LPS to TLR-4, which was also in agreement with the above description. 
The mechanism might first involve a complex formation of LPS/LBP/CD14/MD-2, 
which in turn initiate signaling by complex binding to and aggregating cell surface TLR-
4. These inhibition data also suggested that besides TLR-4, other receptors, such as SR- 
A, might be involved in direct binding of LPS to the cell surface.
The term “scavenger receptor (SR)” covers a wide range of structurally related or 
unrelated membrane molecules expressed mainly by macrophages and endothelial cells. 
To date, numerous polyanionic ligands for SR receptors have been identified. Among 
these, the endocytosis of modified low-density lipoprotein (LDL) by Class A SR (SR-A) 
has been the best characterized. The understanding of the role of SR-A receptor in the
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innate immune system has been developed mainly based on the following evidence. First, 
binding studies have shown that certain conserved molecular features associated with 
pathogens, such as LPS from Gram-negative and LTA from Gram-positive bacteria, 
could compete with some other known ligands for direct binding to SR-A. Such 
observations suggested that SR-A could function as a PRR, activating innate responses 
by direct binding to conserved bacterial structures. Second, SR-A is primarily expressed 
on the cell surface of macrophages, and macrophages are the main players of innate 
immune system that functions as the first line of anti-microbial defense(13). Additional 
evidence indicates that SR-A may function as an adhesion molecule in vitro, and similar 
to other PRR molecules, SR-A may also directly bind to modified -  host components and 
to exogenous ligands, such as LPS and LTA, and in turn mediate endocytosis and 
phagocytosis(11).
However, the intracellular signaling pathways induced by SR-A have been poorly 
defined, as the ligands utilized in many in vitro and in vivo studies could bind to a range 
of SR-A molecules. This makes characterization studies of signal pathways mediated via 
certain receptors very difficult to perform. The structural basis for receptor -  ligand 
interactions, as well as cooperative mechanisms of SR-A with other receptors, therefore, 
also remains unclear. Chapter Four of this study investigated the functions and 
cooperative mechanisms between SR-A and TLR-4 receptors for up-regulating mouse 
APC responses to LPS, as well as to silica and PM1648, the two bioactive particulates 
that have shown implications for adverse health effects, such as silicosis and asthma. The 
pathogenic responses to the bioactive particulates have been suggested to be mediated 
through certain immune system dysfunctions (18,19,2Z\
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In vitro inhibition assays using specific monoclonal antibodies to block either 
receptor, or both, on mouse macrophages, followed by cell stimulation with the bioactive 
particles and LPS were performed in Chapter Four. Similar studies using cells from 
receptor deficient animals were performed as well. By comparing macrophage cytokine 
and T cell cytokine secretion from either wild type or receptor deficient cells, we 
concluded that signaling pathways for LPS and the two bioactive particulates were 
mediated through different receptor combinations. Silica needs both SR-A and TLR-4 to 
“turn on” APC activity’ efficiently, whereas both LPS and PM1648 use TLR-4 for 
macrophage activation. Furthermore, SR-A appeared to be involved in direct binding to 
LPS and PM1648, and might even function as a negative regulator in macrophage 
activation when challenged by LPS and PM1648. The different receptor combinations 
and signaling mechanisms employed by the two particles for activating macrophages 
might contribute differently to lung pathogenicity upon exposure to the particles, as silica 
exposure is mainly related to fibrosis, whereas PM has been known to exacerbate asthma. 
Further in vivo studies with receptor deficient animals being exposed to the particles 
would help confirm the present in vitro findings by observation and measurement of the 
resulting in vivo pathogenic responses to the two types of particles.
Macrophage SR-A receptors include a wide range of surface molecules that are 
involved in receptor-mediated endocytosis of selected polyanionic ligands. Some of these 
receptors also function in phagocytosis of apoptotic cells and bacteria. A previous study 
(96) showed that LPS exposure induced SR-A surface expression on mouse macrophages. 
This phenomenon has been related to the observed resistance towards endotoxemia in 
mice. Additional murine in vivo studies have shown that in LPS -  induced lung injury,
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SR-A could play a protective role by uptake and clearance of LPS and apoptotic cells(97). 
Another previous study conducted at Scripps Research Institute (Tobias, et al, 2004) 
found no involvement of TLR-4 in cellular LPS uptake mechanisms <33). Instead, their 
data indicated that LPS uptake in CD 14-positive monocytes was predominantly mediated 
through a CD14 -  dependent pathway. In CD14-negative endothelial cells, on the other 
hand, SR-A was found to play a critical role in LPS clearance and detoxification. Our 
data presented in Chapters Three and Four are consistent with the previous studies, 
showing that SR-A might be involved in LPS direct binding to the cell surface, but LPS 
binding to SR-A did not transmit signals, suggesting a host protective role of SR-A that 
mediates a disposal system for toxic and pathogenic substances.
Significant numbers of studies have been performed focusing on the effects of 
endotoxin exposure on TLR-4 and SR-A expression(96,91' 99 “ 103). However, there is very 
limited information regarding the effects of particulate exposure on the biosynthesis and 
function of these two receptors. The present study investigated the pretreatment effects of 
the two bioactive particulates, silica and PM1648, on surface expression levels of TLR-4 
and SR-A, and our data indicated that the particulate exposure could increase expression 
of both receptors (data not shown).
It has been well accepted that the physical contact between particulates and the 
cell membrane is the first and critical step for macrophage activation in response to 
particle exposure. Particulates could be uptaken by immunocompetent cells for clearance, 
and such engulfment might trigger different biochemical pathways, leading to cell 
activation. In addition, particulates could be rendered antigenic properties by adsorbing 
proteins, phospholipids, or metal ions on particle surface. SR-A has been suggested to
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possess double functions in host defense system, including a host -  protective role by 
mediating a disposal system for toxic and pathogenic substances, as well as the other 
critical function in both innate and adaptive branches of the immune response. Indeed, 
characterization studies have shown that SR-A played a role in exogenous "antigen 
presentation(98). Therefore, it would be expected that particle exposure could trigger SR- 
A biosynthesis pathways for its enhanced particle clearance and potential antigen 
presentation functions.
Available data also suggested that there might be receptors other than SR-A 
involved in particle signaling(18,22\  The present study indicated that TLR-4 was involved 
in silica and PM1648 signaling for mouse APC activation, but its detailed functional 
mechanism is not yet clear. Based on the available knowledge, TLR-4 mediated LPS 
signaling pathways fall into two categories: the common MyD88 -  dependent pathway 
and the specific Trif -  dependent pathway. The question of whether the same pathways 
are required for TLR-4 mediated particle signaling has not been answered, and this 
question is worth the research effort in the future. In addition, it will be necessary to 
further investigate if other novel pathways and adaptor proteins are involved in TLR-4 
mediated intracellular signaling mechanisms for the bioactive particles. The present study 
also indicated that both silica and PM1648 pre-exposure could increase TLR-4 surface 
expression (data not shown). However, the mechanism of TLR-4 up-regulation by 
bioactive particulate exposure again remains unknown. Therefore, the biological 
significance of differential TLR-4 expression needs to be examined as well.
Previous studies indicated that silica exposure could result in SR-A -  mediated 
caspase activation in macrophages cells, leading to subsequent apoptosis and necrosis (18).
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The present study also indicated that both TLR-4 and SR-A were required for signaling to 
activate mouse APC cells by silica exposure. However, our macrophage cytokine tests 
found no detectable amount of IL-6 and IL-12 p40 from BMDM cells stimulated with 
silica, suggesting that macrophages stimulated with silica sent signals other than soluble 
cytokines to T cells. Previous “trans-well” study results were in agreement with our 
current data, indicating that signal factors other than macrophage cytokines from silica 
treated cells, perhaps membrane bound, had contributions to T cell activation. However, 
information is not available at this point regarding the mechanism implicated in the 
immune responses initiated by silica exposure. It would be of interest to examine and 
identify the signal factors sent by the silica - treated macrophages to the T cells that 
eventually turn on the host defense reaction.
The identification and functional characterization of cell surface pattern 
recognition receptors (PRR) in murine and human models have brought our 
understanding of the innate and adaptive immune system to a new level, but the picture is 
far from complete. The function of these receptors in host defense is so important and 
fundamental, but our knowledge and understanding regarding these receptors is still quite 
limited due to the complication that the PRR function is actually related to most aspects 
of the mammalian immune system. Hence, knock -  out mutations of these critical 
receptors are most likely to cause immunodeficiency. On the other hand, over expression 
of the receptors might result in inflammatory or autoimmune disorders. In the mean time, 
PRRs have also become crucial research targets for immune interventions due to the 
importance of their effects on initiating and directing the adaptive immune responses. For 
example, information obtained from these studies might be potentially useful
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therapeutically, as it might lead to the development of novel agonists or antagonists of 
PRRs as candidates for potential new adjuvant products that function through 
pharmacological manipulation of innate immune responses. The work presented in this 
dissertation focused on two pattern recognition receptors, TLR-4 and SR-A. Although 
progress has been made in characterizing and understanding these two pattern recognition 
receptors, there are still many more unanswered fundamental questions, such as the 
detailed mechanisms of ligand recognition, cooperative mechanisms among different 
receptors, and the different cellular and immune responses induced by various receptor -  
ligand engagements. In the future, the answers to these questions will greatly help us to 
better understand the complicated action force that the host immune system utilizes to 
detect and dispose invading pathogens without destroying self tissues.
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